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ABSTRACT 
Jeremiah Stephen Hinson:  The Regulation of Myocardin Factor Dependent Transcription in 
Vascular Smooth Muscle 
(Under the direction of Christopher P. Mack, PhD) 
 
This work explores the role of the myocardin family of serum response factor (SRF) 
co-factors in smooth muscle cell (SMC) differentiation, and identifies novel modes of 
regulating their activities. Extensive evidence indicates that SRF regulates muscle-specific 
gene expression by binding to conserved promoter regions known as CArG boxes. 
Myocardin and the myocardin-related transcription factors MRTF-A and MRTF-B are all 
capable of potently transactivating SRF-dependent gene expression. The sub-cellular 
localization of MRTFs is regulated by RhoA signaling, an established determinant of SMC 
marker gene activity. Studies included here demonstrate that the MRTFs are expressed in 
primary and cultured SMC and in multiple organs with a large SMC component, and that 
they are capable of upregulating SMC-specific gene activity in multipotential 10T1/2 cells. 
We demonstrate that the myocardin factors have dramatically different localization patterns 
and that the stimulation of SMC-specific transcription by certain RhoA-dependent agonists is 
likely mediated by increased nuclear translocation of the MRTFs. Gel shift assays were used 
to show that myocardin factor activity correlates well with SRF/CArG ternary complex 
formation, and that MRTF-SRF interactions are partially dependent upon CArG sequence. In 
a yeast-two-hybrid screen for novel SRF binding partners in aortic SMC, we identified four 
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and a half LIM domain protein 2 (FHL2). We showed that FHL2 also interacted with all 
three myocardin factors and enhanced myocardin and MRTF-A-dependent transactivation of 
the SM α-actin, SM22, and cardiac ANF promoters by increasing the half-lives of these 
proteins. Treatment of cells with the proteasome inhibitors MG132 and lactacystin strongly 
upregulated myocardin factor protein levels and resulted in a substantial increase in ubiquitin 
immunoreactivity in MRTF-A immunoprecipitants. Importantly, these data are the first to 
indicate that the myocardin factors are regulated by proteasome-mediated degradation, and 
that SRF-dependent gene activity can be upregulated via inhibition of their degradation. We 
have further shown that the muscle-specific ring finger protein MuRF3 physically interacts 
with the myocardin factors and inhibits transactivation of the SM α-actin and SM22 
promoters. MuRF3 also inhibited myocardin factor protein expression, and may act as an E3 
ubiquitin ligase for this very important family of SRF co-factors. 
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BACKGROUND AND SIGNIFICANCE 
VASCULOGENESIS AND ANGIOGENESIS 
A functioning circulatory system is required very early in mammalian development, 
when diffusion from surrounding uterine tissues becomes inadequate to supply all cells of the 
growing embryo with appropriate levels of oxygen. Mice unable to establish such a 
circulatory system die by embryonic day 10, and numerous human diseases involve 
alterations in circulatory system function and oxygen delivery (143). Blood vessel formation 
during embryogenesis is accomplished de novo via vasculogenesis, a process that involves 
the recruitment of progenitor cells from the mesoderm to previously avascular areas within 
the embryo. These angiogenic precursor cells differentiate into endothelial cells and coalesce 
to form a rudimentary tube network, referred to as the primary vascular plexus (130, 131). 
The vascular plexus supplies the very early embryo with adequate amounts of blood, but 
increasing oxygen demands stimulate increased vascularization via the process of 
angiogenesis, defined by the budding or sprouting of new endothelial capillary branches from 
pre-existing blood vessels (54).  
Further vascular development requires the transformation of newly formed 
endothelial tubes into multi-layered arteries and veins. This process is highly dependent upon 
the investment of endothelial tubes with a medial layer of smooth muscle cells (SMC), which 
will provide the vasculature with a capacity for contraction, and throughout the life of the 
organism function in the regulation of blood pressure, blood distribution, and vessel tone 
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diameter. Larger vessels also become invested with an outer layer comprised of fibroblasts 
and extracellular matrix that provides further structural support and cushioning for the 
vasculature. As demonstrated in figure 1.1A, the result of these developmental processes is a 
mature blood vessel consisting of three layers: the intima (endothelial cells and basement 
membrane), media (SMC and their extracellular matrix), and adventitia (fibroblasts and their 
exracellular matrix) (143).  
THE VASCULAR SMOOTH MUSCLE CELL: ORIGINS AND FUNCTION 
 At least three distinct embryological origins of vascular SMC have been 
experimentally identified in chick and mouse (see (61) for review). The cardiac outflow tract 
and pharyngeal arch arteries contain SMC derived from cardiac neural crest cells(75), while 
the media of the nearby coronary arteries is comprised of SMC that arise from mesothelial 
progenitors within the proepicardial organ (102). The remainder of the vasculature is 
populated with SMC that are derived largely from lateral and/or splanchnic mesoderm (65).  
Several recent studies have suggested that at least some SMC may also be derived directly 
from endothelial progenitor cells, through transdifferentiation of mature endothelial cells, or 
from persisting stem cell populations in adult organisms (61). 
 Mature SMC are highly specialized cells that normally proliferate at very low rates 
and whose primary function is contractile. SMC differentiation is measured by the expression 
of a unique set of marker genes that includes the contractile and contractile-associated 
smooth muscle myosin heavy chain (SM MHC), smooth muscle α-actin (SM α-actin), 
smooth muscle 22α (SM22), telokin, and calponin (see (122) for review). Unlike skeletal and 
cardiac myocytes, SMC do not undergo terminal differentiation. Instead, SMC retain a 
 3 
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plasticity that allows them to undergo significant and reversible changes in phenotype in 
response to environmental cues, even as fully mature cells. These changes occur through a 
process known as phenotypic switching (or phenotypic modulation), and are accompanied by 
often dramatic shifts in gene expression toward a profile resembling that of more 
proliferative and synthetic progenitor cell types. Phenotypic switching of SMC is very 
important for vascular morphogenesis and injury repair. Increases in proliferative, migratory, 
and synthetic capacities of SMC allow their growth into areas of new vascularization during 
development, and in response to certain types of vascular insults, facilitates similar roles in 
injury response (14), (122).   
SMOOTH MUSCLE CELLS IN CARDIOVASCULAR DISEASE 
  While it is clear that a capacity for phenotypic switching is critical for proper 
function of SMC, in response to abnormal external cues, it can also lead to their involvement 
in multiple human diseases. Phenotypic modulation of SMC has been implicated in the 
pathogenesis of such diseases as atherosclerosis, restenosis, hypertension, and cancer. 
Atherosclerosis is the most common disease associated with SMC, and it appears that SMC 
play both pathologic and protective roles in its progression, as shown in figure 1.1B and 
discussed below (14).  
 SMC are one of the many cell-types implicated in the initiation of atherosclerosis that 
also includes endothelial cells, lymphocytes, monocytes, and macrophages (90). 
Phenotypically modulated SMC contribute to atherogenesis partly through increased 
production of proteases (44), inflammatory cytokines, and inflammatory cell markers (134, 
136). The production of these factors results in recruitment and activation of leukocytes, 
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endothelial cell dysfunction, and increased proliferation of SMC themselves (34). Increased 
SMC growth and proliferation contribute to plaque expansion through increased intimal 
migration and increased production of extracellular matrix (169). SMC also directly promote 
lipid deposition within plaque. Not only are SMC capable of lipid uptake and foam cell 
transformation themselves (135), in concert with endothelial cells they also interact directly 
with recently recruited monocytes and facilitate their differentiation into macrophages (154), 
the major precursors of foam cells and source of lipid in the plaque. This interaction is 
facilitated in part via cell surface receptors (ie. VCAM-1 and ICAM-1) that are not expressed 
in SMC except during atherosclerosis (10, 37). SMC simultaneously play a protective role in 
atherosclerosis by contributing to formation of the plaque’s fibrous cap. This cap is important 
for plaque stabilization, and helps to prevent of rupture and thrombosis (44). The protective 
role of SMC in atherosclerosis is accomplished via many of the same mechanisms that 
facilitate their pathological role, including increases in proliferation and intimal migration, 
and increased production of extracellular matrix. 
 Blockage of vessels due to atherosclerosis is commonly treated using balloon 
angioplasty and stent placement. While these procedures successfully clear atherosclerotic 
plaques, up to 50% of patients present with recurrence of symptoms due to post-angioplasty 
restenosis (150). Restenosis is characterized by intimal hyperplasia that leads to further 
luminal narrowing and vessel occlusion. This is caused in large part by aberrant growth and 
proliferation of medial SMC following mechanically-induced denuding of the endothelium 
(108). The development and experimental implementation of many elegant animal models 
has yielded a great deal of information regarding the pathogenesis of both atherosclerosis and 
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restenosis (2, 186), yet many of the molecular mechanisms governing initiation of SMC 
involvement remain to be determined. 
Systemic hypertension, a complex disorder involving many factors, is characterized 
by increases in SMC contractility and vascular tone, as well as increases in SMC growth and 
synthesis of matrix materials (42, 111). These alterations in SMC function result in increased 
peripheral resistance, and elevated blood pressures. Similar changes in SMC function outside 
the vasculature are also believed to lead to their involvement in the progression of such 
diseases as athsma, obstructive bladder disease, and numerous reproductive disorders (122).  
Additionally, phenotypic switching of SMC plays a significant role in the progression 
of many cancer types. Tumor growth is dependent upon increased oxygen supply via 
neovascularization, and larger tumors require larger vessels.  Oftentimes, moderate to large 
diameter vessels formed via tumor-associated angiogenesis are underinvested with SMC or 
invested with poorly differentiated SMC, leading to leaky vasculature and increased 
opportunity for metastasis (107). The mechanisms responsible for defective SMC recruitment 
and differentiation observed in tumor-associated angiogenesis are poorly understood, and a 
greater understanding of the mechanisms governing SMC differentiation in development will 
undoubtedly aid in their dissection.  
ENVIRONMENTAL CONTROLS OF SMOOTH MUSCLE CELL GROWTH AND DIFFERENTIATION 
It is well established that SMC growth and differentiation are regulated by a complex 
array of local environmental cues including growth factors, contractile agonists, cell-cell and 
cell-matrix interactions, inflammatory stimuli, reactive oxygen species, and mechanical 
stresses (see (122) for review). However, the signal transduction pathways by which these 
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cues are transmitted to the nucleus, and the mode by which these cues promote either growth 
or differentiation, have not been well elucidated. An extensive review of this field is beyond 
the scope of this dissertation, but several studies are worth noting.  
The D’Amore laboratory has demonstrated that co-culture of endothelial cells (EC) 
with 10T1/2 smooth muscle precursor cells leads to an increase in SMC differentiation 
marker gene expression in a manner that is dependent upon cell-cell contact, and that is 
mediated at least in part by transforming growth factor (TGF)-β signaling, a factor that has 
been shown to up-regulate SMC marker gene expression by many groups (33, 62, 122).  
Vascular endothelial growth factor (VEGF) has been shown by the same group to promote 
migration of SMC in culture (49), and several studies have strongly implicated platelet-
derived growth factor (PDGF)-BB in the down-regulation of SMC differentiation marker 
genes and promotion of SMC growth and proliferation (7, 63, 83). An increasing number of 
agents appear to be capable of promoting both growth and differentiation in SMC. For 
example, we have recently identified the lipid agonist shingosine-1-phosphate (S1P) as a 
stimulator of early response gene and differentiation marker gene expression in SMC. We 
demonstrated that S1P activates multiple signaling pathways in SMC, including those of 
MAPK and RhoA, and that the end result of S1P-initiated signaling may depend largely upon 
competition between transcription factors in the nucleus (88).  
Many of the findings above have also been supported by work in animal models. The 
importance of S1P signaling for SMC function was first illustrated in vivo by global 
knockout of Edg-1, a G-protein coupled receptor for S1P. Mice homozygous for this deletion 
died in utero due to defective SMC recruitment and function in established vasculature (87). 
Importantly, a similar effect was seen upon endothelial cell-specific deletion of this receptor, 
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indicating that Edg-1 activity in endothelial cells is important to SMC function (1). A further 
illustration of cross-talk between the endothelium and SMC was seen with the knockout of 
the Krupple-like transcription factor KLF2. In this model, KLF2 was expressed in endothelial 
cells but not SMC, yet its deletion was embryonic lethal due to in part to defective SMC 
maturation (71). Further analysis of KLF2-/- embryos revealed defective SMC migration in 
the developing vasculature (185). A similar phenotype is seen upon genetic deletion of 
PDGF-BB or its ligand (76, 85). Interestingly, PDGF-BB has been suggested to exert its 
effects on SMC function via KLF2  (185).  Furthermore, genetic deletion of any one of a 
number of TGF-β signaling components, including TGFβ1 and two different TGF-β 
receptors results in embryonic lethality due in at least in part to defective vascular 
development and/or defective SMC differentiation (32, 119, 121). There are many other 
external cues regulate SMC function, and there is still much to be learned regarding SMC 
signal transduction pathways. However, it is clear that the small GTPase RhoA and the 
myocardin family of transcription factors (both discussed below) play important roles in 
coordinating many of these signals.  
THE CARG BOX: AN ESSENTIAL DNA ELEMENT FOR GROWTH AND DIFFERENTIATION 
In 1985, Treisman et al discovered a region within the promoter of the early growth 
response gene c-fos that was highly sensitive to serum stimulation and displayed all the 
characteristics of a classic enhancer element (166). Further studies of this enhancer region 
revealed that it contained a critical protein-binding sequence, which was later termed the 
serum response element (SRE) (46, 128, 164). The c-fos SRE was initially described as a 23-
bp stretch of DNA with the sequence aggatgtccatattaggacatct, displaying repeats of inverted 
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dyad symmetry (regions of inverted dyad symmetry indicated by bolded type) (164). Almost 
simultaneously, a region of DNA with high sequence homology to the SRE core was 
discovered in the promoter of the cardiac α-actin gene. This region lacked the dyad 
symmetry of the SRE, and was described as a 10-bp stretch with the sequence CC(A/T6)GG 
(103). The cardiac α-actin sequence was later termed the “CArG box”, and similar CArG 
boxes were soon discovered in the promoters of multiple muscle-restricted genes, including 
skeletal α-actin, alpha myosin heavy chain, myosin light chain, and cardiac troponin T (99, 
103). Over 60 genes have since been identified which contain an SRE or CArG box variant 
sequence within their promoters, with a very high percentage of these being growth or 
muscle-restricted genes (see (99) for review). 
Nearly every SMC differentiation marker gene described to date contains at least one 
CArG box in the vicinity of its promoter (122). Several SMC genes, including SM MHC and 
SM α-actin, contain multiple CArG elements, each of which appear to be required for proper 
expression of these genes in vivo (91, 96). Mack et al illustrated this paradigm using multiple 
deletion variants of a Lac Z transgene driven by the SM α-actin promoter. Mutation of any 
one of the three SM α-actin CArG boxes resulted in a loss of expression in smooth muscle-
containing tissues (Fig 1.2). While it is still not entirely clear how multiple CArG elements 
function together within a single gene, it has been suggested that the multi-protein complex 
required for transcription of SMC differentiation marker genes may rely on transcription 
factor binding at each CArG, which would in turn facilitate further interactions between 
components of the transcriptional machinery (93). This continues to be an important area of 
study in the field. 
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REGULATION OF SMOOTH MUSCLE CELL DIFFERENTIATION BY SRF 
Serum response factor (SRF) was originally purified and cloned based upon its 
interaction with the c-fos SRE, and was named based upon that interaction (116, 163). The 
central CArG box within the SRE was determined to be the sequence required for SRF 
binding, and later studies showed that the bases flanking the CArG box mediated interactions 
between the SRE and additional transcription factors known as the ternary complex factors 
(TCFs) (see (165) for review). The importance of SRF-cofactor interactions will be discussed 
later in this chapter. 
SRF has been extensively studied since its discovery (see (99) for review). The 64 
kDa transcription factor contains 508 amino acids and belongs to the MADS (MDM1, AG, 
DEFA, and SRF) family of proteins. These proteins are characterized by the presence of a 
conserved 56 amino acid region referred to as the MADS box. This region is comprised of an 
amino-terminal DNA binding domain, a dimerization domain, and a domain capable of 
mediating interactions with accessory factors (148). As shown in figure 1.3A, the MADS box 
of SRF occupies amino acids 142-223 and is flanked by an amino terminal nuclear 
localization signal (aa 95-100) and a carboxy-terminal transactivation domain (265-508)(45, 
99, 105). SRF binds to the CArG box of target genes as a homodimer, where it interacts with 
various accessory factors, and activates gene expression via its carboxy-terminus.  
SRF activity has been shown to be critical for processes central to development in 
multiple species. Genetic deletion of SRF in the mouse leads to lack of mesodermal 
formation and a halt in development at gastrulation (4). Similar deletion of SRF in other 
organisms including Dictyostelium, Caenorhabditis elegans, and Drosophila melanogaster, 
as well as in mouse embryonic stem cells have revealed that SRF is essential to the processes 
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of cell migration and adhesion, cytoskeletal structure formation, and animal movement (38, 
43, 50, 141). The early lethality of SRF null mice has made traditional SRF lack of function 
studies in more differentiated cell types difficult.  Recently, Miano et al partly overcame this 
issue by using Cre-lox technology to generate a line of mice in which SRF is selectively 
deleted in the cardiovascular system (101). Mutant mice in this study survived past 
gastrulation but died later in development due to incomplete development of the heart and 
vasculature. Ultrastructural examination of cardiomyocytes and SMC in these mice 
confirmed previous reports that SRF plays a vital role in cytoskeletal structure and contractile 
function. 
Soon after the initial discovery that SRF interacted with the SRE CArG, an 
independent report indicated that it also interacted with the cardiac α-actin CArG, albeit with 
a lower affinity than seen with the SRE in tandem experiments (9). These studies were the 
first to suggest that SRF may be responsible for positively regulating the expression of both 
growth genes and muscle differentiation genes, a surprising finding considering that these 
gene expression programs are somewhat opposing.  We and others have demonstrated that 
SRF also regulates nearly all of the known SMC differentiation marker genes, indicating that 
it is a key regulator of SMC differentiation. As is true for growth genes and skeletal and 
cardiac muscle genes, SRF binds to the multiple CArG boxes that are found in the promoters 
of nearly all of the SMC differentiation marker genes to regulate their expression (Fig 1.3B) 
(55, 79, 91, 93, 95, 100).  
 While recent studies have shown that differentiation of skeletal and cardiac muscle is 
controlled by the expression of master regulatory transcription factors that work in concert 
with SRF such as MyoD, Nkx2.5, and Gata-4 (120, 127, 160), a transcription factor that 
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specifies SMC lineage or completely explains SMC-specific transcription has not yet been 
described. SRF is expressed highly in all three muscle cell-types during development (28), 
but as described above, is a ubiquitously expressed protein that also regulates the expression 
of a variety of other CArG-containing genes including the growth genes, c-fos and egr-1, as 
well as the expression of several skeletal- and cardiac-specific genes (11, 21, 152, 165, 173). 
While the molecular mechanisms by which SRF regulates these disparate gene programs are 
still not completely known, it is clear that mechanisms in addition to the presence and 
activity of SRF must exist that regulate SMC-specific transcription. 
REGULATION  OF  SRF  FUNCTION  VIA  COFACTOR  INTERACTIONS 
 A large number of studies have established the paradigm that SRF function is 
regulated to a great extent by interaction with other transcription factors or co-factors. The 
first SRF co-factors identified, the ternary complex factors (TCFs), Elk-1, Sap-1, SAP-
2/NET/ERP, regulate early response gene expression. These transcription factors are 
activated by growth factor signaling and only bind SRF after they have been phosphorylated 
by MAP-kinase (30, 56, 97).  Based upon the demonstration of a SMC-selective SRF 
complex in gel shift analyses, our laboratory was one of the first to suggest that SMC-
specific transcription was regulated by a similar mechanism (93). Chang et al later 
demonstrated that SRF associates with the SMC-selective cysteine- rich LIM-only proteins, 
CRP1 and CRP2, to enhance SMC differentiation marker gene expression (20). Since the 
CRPs do not contain transcription activation domains, it is likely that these proteins act as 
adapter molecules to facilitate interactions between SRF and other transcription factors 
including the GATA proteins.  Indeed, SRF has been shown to interact with GATA-4 and 
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Nkx2.5 to regulate cardiac-specific gene expression and MyoD and myogenin to regulate 
skeletal muscle-specific gene expression (21, 22, 48, 145).  Interestingly, forced expression 
of CRP2 has recently been shown to activate SRF-dependent SMC gene activity in adult 
mouse cardiomyocytes via an interaction with Brg-1, a component of the SWI/SNF 
chromatin remodeling complex. Brg-1 was also shown to interact with GATA-4, 
strengthening the idea that the CRPs may function to facilitate interactions between various 
components of the transcriptional complex (18).   
 Philippar et al have implicated an additional LIM-only protein, four and a half LIM 
domain protein 2 (FHL2), as a binding partner of SRF that also modulates its activation of 
SMC differentiation marker genes. FHL2 is unable to bind to DNA directly, but was shown 
to be present at the promoters of SMC differentiation marker genes (but not of growth genes) 
following activation of RhoA signaling (discussed below). The authors of this study reported 
that FHL2 functioned as an inhibitor of SRF-dependent SMC gene activation by FHL2, and 
that this was accomplished via inhibition of higher order complex formation between SRF 
and another cofactor (124). Prior to the publication of this srudy, we independently detected 
an interaction between FHL2 and SRF in human aorta using a genetic screen approach. We 
have subsequently found FHL2 to be both a positive and negative regulator of SMC 
differentiation marker gene expression, depending upon its interactions with additional SRF 
cofactors. The details of these studies will be discussed at length in a later chapter. 
ACTIVATION OF SRF-DEPENDENT GENE EXPRESSION  BY THE SMALL GTPASE RHOA 
As discussed previously, SMC growth and differentiation are controlled by a diverse 
array of extrinsic factors, but the cell signaling mechanisms by which these factors initiate 
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SRF-dependent transcription of SMC differentiation marker genes is not well understood. 
Our laboratory group and others have recently demonstrated that the regulation of SRF-
dependent transcription, including that of SMC differentiation marker genes, is accomplished 
at least in part by signaling through the small GTPase RhoA.  
The binding of GTP regulates small GTPase activity, and the Rho family of small 
GTPases cycle continuously between active GTP-bound and inactive GDP bound forms (6). 
RhoA is activated by multiple serum components, many of which signal through G-protein 
coupled receptors (GPCRs). Agonists shown to activate RhoA in SMC include platelet-
derived growth factor, angiotensin II, lipophosphatidic acid (LPA), and S1P (88, 112). The 
Treisman laboratory was the first to show that activation of RhoA could lead to an up-
regulation of SRF-dependent genes. These studies focused on the c-fos promoter, and also 
showed that RhoA was capable of activating the expression of early response genes in a 
TCF-independent fashion (57). Additional studies have shown that the effects of RhoA on 
SRF-dependent transcription require RhoA-mediated actin polymerization and possibly 
reductions in G-actin pools (152). RhoA signaling has also been shown to be important in the 
regulation of multiple SRF-dependent skeletal muscle differentiation marker genes (159, 
181) and cardiac genes during hypertrophy (3). Interestingly, a link between SMC-specific 
gene expression was made by Mack et al who showed that SMC differentiation marker gene 
expression is upregulated in response to RhoA activation, and that this upregulation is 
dependent upon RhoA-mediated actin polymerization (92). In addition, it has been reported 
that RhoA-mediated actin reorganization is also required for the differentiation of coronary 
SMC from proepicardial cells (89). Collectively, these studies suggest that RhoA signaling is 
an important point of convergence for the multiple external cues that promote SMC 
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differentiation. However, until recently, no factors had been identified which linked 
cytoplasmic activation of RhoA with up-regulation of SMC marker genes in the nucleus. 
COACTIVATION OF SRF BY MYOCARDIN 
 An important breakthrough in the study of the molecular mechanisms that regulate 
SMC differentiation came in 2001 with the discovery of the myocardin family of SRF co-
factors by Wang et. al (175). This family includes myocardin as well as two Myocardin-
Related Transcription Factors, MRTF-A/MKL-1/Mal and MRTF-B/Mkl-2 (176).  Myocardin 
was identified through a bioinformatics-based screen of cardiac-specific expression sequence 
tags, and results from Northern analysis initially showed that myocardin was specifically 
expressed in the myocardium of adult mice. In situ analysis demonstrated that myocardin was 
expressed very early during cardiac development, but interestingly, was also detected in a 
subset of developing smooth muscle that included the aortic arch, pulmonary outflow tract, 
lung, esophagus, and gut. Later studies confirmed and extended myocardin’s expression 
pattern to the heart and most developing and adult SMC compartments including dorsal 
aorta, bladder, stomach, intestines, and uterus (36, 176). 
 Myocardin localization to the nucleus suggested that it played a role in transcriptional 
regulation, and Wang et al went on to show that myocardin powerfully transactivated a 
number of cardiac and SMC-specific genes in Cos7 cells including ANF, Nkx2.5, and SM22 
(175, 176). Myocardin has no consensus DNA binding domain, but these authors presented 
several lines of evidence strongly indicating that myocardin was recruited to CArG-
containing genes by a direct physical interaction with SRF.  First, CArG mutations that 
prevented SRF binding also inhibited myocardin’s ability to transactivate the SM22 
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promoter.  Second, myocardin and SRF were shown to physically interact by 
coimmunoprecipitation and gel shift studies.  Finally, myocardin was unable to transactivate 
the SM22 promoter in SRF -/- ES cells, an ability that could be rescued by re-expression of 
SRF.  
 Subsequent studies demonstrated that myocardin was very important for regulating 
SMC-specific gene expression. Chen et al demonstrated that myocardin was expressed 
robustly in rat aortic media and that this expression was attenuated upon culture of rat aortic 
SMC (23). Interestingly, loss of myocardin expression correlated well with loss of SM MHC 
and SM-calponin expression that is frequently seen in cultured SMC, and over-expression of 
myocardin was sufficient to restore calponin promoter activity in these cells. It was 
eventually shown that myocardin could strongly transactivate most, if not all, of the CArG-
containing SMC differentiation marker gene promoters including SM MHC, SM22, calponin, 
and SM α-actin in a variety of cell types including SMC (36, 179, 189).  Importantly, forced 
expression of myocardin was sufficient to activate the endogenous expression of SMC 
differentiation marker genes in a number of non-SMC cell-types including mouse ES cells, 
10T1/2 cells, NIH 3T3 fibroblasts, L6 myoblasts, and cardiac fibroblasts indicating that 
myocardin was sufficient to activate the SMC gene program (23, 36, 179, 189).  
 Studies in vitro and in vivo have indicated that myocardin is required for SMC-
specific gene expression and SMC differentiation. Several groups used dominant negative 
myocardin variants (lacking the transactivation domain) and siRNAs to inhibit SMC 
differentiation marker gene expression in primary rat aortic SMC, and A7r5, Pac1 and A10 
SMC lines (36, 179, 189).  Importantly, Li and associates confirmed a requirement for 
myocardin in SMC differentiation by introducing a deletion in the mouse genome at a locus 
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that encoded for 3 myocardin domains that were shown to be essential for its activity (Basic, 
Q-rich, and SAP, see below) (82). Mouse embryos homozygous for this deletion died at 
E10.5 due to hemorrhage. Examination of myocardin -/- embryos at E9.5 revealed normal 
heart development but severe defects in vascular development, including a reduction of 
vessels in the yolk sac and underdevelopment of the dorsal aorta. Immunohistochemical 
staining for PECAM indicated that endothelial cell differentiation and initial formation of the 
dorsal aorta were unaffected, but staining for SM α-actin, a marker normally expressed in the 
aorta at this time-point, revealed a complete lack of SM α-actin positive cells. These results 
indicated that while myocardin may be a redundant factor in the regulation of cardiac 
development, it is critically important for SMC differentiation, and further, that SRF is 
insufficient to confer SMC lineage in the absence of myocardin. An additional study by 
Parmacek and associates, which utilized Cre-lox technology to ablate expression of 
myocardin specifically in neural crest-derived SMC, further confirmed that myocardin is 
required for expression of SRF-dependent SMC differentiation marker genes. Mice deficient 
for SRF expression in neural crest-derived SMC displayed a lack of contractile SMC gene 
expression in this cell subset, and died prior to postnatal day 3 due to lack of ductus arteriosis 
closure (64). 
 While the importance of myocardin in the regulation of SMC differentiation has 
clearly been established, several studies suggest that myocardin does not entirely explain 
SMC lineage determination. For example, myocardin is not expressed in all developing SMC 
and detection of several SMC differentiation markers preceded detectable myocardin mRNA 
expression in the dorsal aorta (36). While these results obviously depended upon the 
sensitivity of in situ and immunohistochemical analyses for proteins that differ widely in 
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their expression levels, these observations may indicate that mechanisms independent of 
myocardin expression might specify SMC lineage in the vasculature.  It has also recently 
been reported that forced expression of myocardin in primary SMC, ES cells, or 10T1/2 cells 
was incapable of inducing expression of the few SMC marker genes that do not contain 
CArG elements, including smoothelin-B, ACLP, and FRNK and inappropriately activated 
skeletal- and cardiac-specific gene expression (188), further indicating that mechanisms in 
addition to myocardin may be required for SMC differentiation. 
MYOCARDIN DOMAIN STRUCTURE 
Deletion and domain mapping studies have identified a number of regions in 
myocardin that are important for its function (see Figure 1.4) (175). Myocardin contains a 
basic region that is important for nuclear localization, and along with the Q-rich domain, 
mediates its binding to the MADS box domain of SRF.  The very strong trans-activation 
domain (TAD) found at the C-terminus seems to function as a general TAD in that it can be 
replaced by the TAD from VP16 without significant changes in protein function or 
specificity. Myocardin is a member of the SAP (SAF-A/B, Acinus, PIAS) family and this 
domain has been linked to chromatin remodeling and nuclear matrix binding. Although the 
precise function of the SAP domain remains unclear, its deletion inhibited myocardin’s 
ability to transactivate the ANF promoter without affecting its ability to activate the SM22 
promoter indicating that it may be important for gene-specific regulation (175).  The N-
terminal region has an overall inhibitory effect on transcriptional activity as well as on 
MRTF-A’s ability to associate with SRF in gel shift assays (104). It also contains several 
RPEL motifs that have been implicated in the regulation of MRTF-A nuclear translocation 
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by RhoA (see below) (104). Finally, myocardin contains a leucine zipper region that 
mediates homo-dimerization and possibly hetero-dimerization with MRTFs (36, 104, 179).  
Interestingly, Creemers et al have recently discovered an alternative splice variant of 
myocardin that is expressed specifically in smooth muscle (27). This variant contains an 
additional 44bp exon that harbors an early termination codon after amino acid 40 of 
myocardin. Re-initiation of translation from a second start site gives rise to an 856aa protein 
product (as opposed to the full-length 935aa version) that includes all components necessary 
for transactivation, but lacks 79aa of the N-terminal region (see Figure 1.4). The authors of 
this study demonstrated that both the smooth muscle (856aa) and cardiac (935aa) variants of 
myocardin were capable of transactivating SRF/CArG-dependent transcription, but that the 
935aa cardiac variant alone was also capable of transactivating promoters driven by the SRF-
related MADS box protein MEF-2. As MEF-2 is required for the expression of multiple 
cardiac marker genes (84, 114), the existence and expression patterns of these two versions 
of myocardin indicate that they may play an important role in cardiac versus smooth muscle 
cell fate determination. 
MYOCARDIN RELATED TRANSCRIPTION FACTORS, MRTF-A AND MRTF-B 
The myocardin-related transcription factors, MRTF-A/MAL/MKL-1 and MRTF-
B/MKL-2 are also involved in the regulation of SRF-dependent transcription. All three 
myocardin family members have very similar domain structures with greater than 60% 
homology in their N-terminal, basic, Q-rich, and SAP domains and approximately 35% 
homology overall (176) (Fig 1.4).  Unlike myocardin whose expression is specific to cardiac 
and SMC, the MRTFs are expressed more widely. Northern analysis has shown that MRTF-
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A message is expressed in nearly all adult tissues, with strongest expression reported in heart, 
aorta, bladder, skeletal muscle, spleen, and brain (35, 176). In agreement with its widespread 
in vivo expression, MRTF-A is also expressed in multiple cell lines, including primary rat 
aortic SMC, the A7R5, A10, and PAC-1 SMC lines, mouse embryonic stem cells, 10T1/2 
mutipotential cells, C2C12 skeletal myoblasts, and NIH 3T3 fibroblasts (35, 88).  MRTF-B 
expression in adult mice is somewhat more restricted, but based on Northern analysis, it is 
expressed in heart, brain, testis, liver, and lung (176). In a separate study in humans, Selvaraj 
et al detected high levels of MRTF-B/MKL-2 message in skeletal muscle and lower levels in 
brain, heart, placenta, liver, kidney, and pancreas. These authors also detected MRTF-B and 
in mouse C2C12 skeletal myoblasts (142).  
Similar to myocardin, MRTF-A transactivates many muscle-specific SRF-dependent 
genes, and several lines of evidence suggest that MRTF-A regulates SMC-specific gene 
expression perhaps in concert with myocardin. First, while initial results indicated that 
MRTF-A was not detected in the developing aorta, several groups have shown that MRTF-A 
message and protein are expressed highly in aortic SMC, a number of SMC cell lines, and in 
other tissues with large SMC components suggesting that it may play a role in regulating 
transcription in SMC (35, 88).  Second, several laboratories including our own have shown 
that MRTF-A up-regulates most of the SMC-specific differentiation marker gene promoters 
(including SM MHC) to a level equal to or greater than that of myocardin (16, 35, 88, 142). 
Most of these studies have been performed in cell-types that do not express myocardin 
indicating that MRTF-A is sufficient for this response. Third, we and others have used 
dominant negative MRTF-A variants that lack the transactivation domain to inhibit SMC-
specific promoter activity (16, 35, 88, 142).  A potential weakness of this approach is that 
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these variants show some specificity toward MRTF-A, but they also strongly affect 
myocardin-dependent transcription (35), making it difficult to interpret experiments in SMC 
that express both transcription factors. Finally, the importance of the LZ motif for both 
myocardin and MRTF-A activity strongly suggests that dimerization of these transcription 
factors is important for their function. MRTF-A and myocardin have been shown to interact 
by yeast 2 hybrid as well as co-immunoprecipitation (35). Thus, the expression of both of 
these transcription factors in at least some SMC compartments indicates that it is likely that 
they interact to regulate SMC-specific transcription.  
The third myocardin family member, MRTF-B/MKL2, has also been implicated in 
CArG-dependent transcription (16, 176). In the original report by Wang et al MRTF-B had a 
much smaller effect on SM22 or ANF promoter activity than did myocardin and MRTF-A 
(176). However, its human homologue, MKL-2, was shown to strongly activate the SM22, 
ANF, and SM α-actin genes in HeLa cells (142). The role of both MRTFs in SMC-specific 
transcription is further examined in this dissertation research. 
MYOCARDIN FACTOR HOMO- AND HETERO-DIMERIZATION  
One interesting aspect of the myocardin factors is the potential homo- and hetero-
dimerization that can occur between the members of this transcription factor family. As 
stated previously, all three myocardin family members contain a highly conserved coiled-coil 
leucine zipper motif that has been shown to mediate direct interactions between these 
proteins.  Disruption of this domain in myocardin, MRTF-A, or MRTF-B drastically reduced 
transactivation by all of these transcription factors (35, 142, 179) indicating that homo- 
and/or hetero-dimerization is important for their activity.   
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Based on gel mobility shift assays Wang et al suggested that myocardin binds SRF as 
a monomer (179). Since myocardin preferentially activates promoters with multiple CArG 
elements (175), these authors proposed a model in which dimerization between myocardin 
bound to neighboring CArG elements leads to exposure of an otherwise cryptic TAD. This 
could explain both myocardin’s preference for promoters with multiple CArG elements and 
the requirement for multiple CArGs in many of the SMC differentiation marker genes. 
The demonstration of heterodimeric interactions between myocardin family members 
may make this model somewhat more complicated in cell-types such as aorta that express 
more than one of these transcription factors (35, 88). In addition, evidence suggests that 
MRTF-A, in contrast to myocardin, preferentially binds SRF as a dimer (104), raising the 
possibility that MRTF-A and myocardin could simultaneously bind the same CArG element 
under certain conditions. Clearly, more information is needed concerning the requirements 
for formation of the CArG/SRF/myocardin factor ternary complex as well as on the potential 
interactions between myocardin family members.  
REGULATING SMC DIFFERENTIATION VERSUS SMC GROWTH 
Given SRF’s ubiquitous expression pattern and its promiscuous involvement in a 
number of gene regulatory programs, including the immediate early response, it has been 
difficult to explain how SRF regulates cell-type-specific gene expression. An important 
observation in this regard is that, in general, myocardin and MRTF-A transactivate gene 
promoters that contain multiple CArG elements much more strongly than those regulated by 
a single CArG resulting in preferential activation of the SMC-specific promoters over the 
early response growth genes (175).  In addition, dominant negative forms of MRTF-A had 
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little effect on the expression of c-fos, providing further support for differential effects of the 
myocardin family on SRF-dependent differentiation and SRF-dependent growth (16).  As 
previously discussed, LZ domain-mediated interactions between myocardin molecules bound 
to separate CArG elements may at least partially explain myocardin’s selective effects on 
SMC differentiation marker gene expression.   
Another important observation made by Wang et al was that competition for SRF 
binding between myocardin and the TCFs may be involved in regulating SRF-dependent 
differentiation versus growth (178).  Using gel shift and co-immunoprecipitations, these 
authors showed that myocardin and Elk-1 competed for binding to the same SRF domain 
within the MADS box, and that activation of MAP-kinase signaling by PBGF-ΒΒ could 
increase Elk-1-SRF association at the expense of myocardin-SRF association.  They also 
found that mutation of a potential Elk-1 binding site in the SM22 promoter resulted in 
continued transgene expression in the heart after the wild-type transgene had been down-
regulated.   
Additionally, there is evidence indicating that myocardin factors may preferentially 
bind to certain CArG elements over others. Chromatin immunoprecipitation assays showed 
that MRTF-A interacted with SRF bound to the CArG boxes within the vinculin and SRF 
promoters but not with SRF bound to the c-fos or egr-1 promoters (104). A better 
understanding of interactions between the different myocardin family members and specific 
SRF-CArG complexes will be important for delineating the role of the myocardin family in 
both cell-type-specific and gene-specific transcriptional regulation.  
REGULATION OF MYOCARDIN 
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Very little is known about the regulation of myocardin expression and/or activity. 
One of the first parameters shown to affect myocardin-dependent transactivation was SRF 
expression levels, with excess SRF leading to attenuation of myocardin activity (175). All 
three muscle cell types express high levels of SRF which may partially explain why 
myocardin trans-activates the SMC-specific genes relatively weakly in SMC (10-20 fold) 
compared non SMC-types (>200 fold) (23, 176, 189). The precise mechanism for this 
inhibition is unknown, but these data suggest that SRF and myocardin can associate in 
transcriptionally inactive complexes, possibly in the absence of SRF-DNA binding. 
Interestingly, myocardin has also been shown to physically bind to GATA-4, an interaction 
mediated by the SAP domain (118). Depending upon the CArG-dependent promoter studied, 
this interaction either stimulated or inhibited promoter activity providing further evidence 
that complex interactions between myocardin, SRF, and other transcription factors is 
probably important for regulating muscle-specific transcription. 
Several studies have shown that myocardin expression can be altered by extrinsic 
factors that are known to have effects on SMC differentiation.  Yoshida et al demonstrated 
that treatment of primary rat aortic SMC with angiotensin II increased myocardin expression 
in a dose-dependent manner and that this increase correlated with increased expression of 
SM α-actin (187).  Wamhoff et al from the same group also showed that membrane 
depolarization with KCl led to an increase in myocardin expression (174).  The observed 
increase in this model was mediated by intracellular calcium and RhoA signaling in that it 
could be inhibited by the calcium channel blocker, nifedipine, or the Rho-kinase inhibitor, Y-
27632. The molecular mechanisms that control myocardin expression have been examined 
by Ueyama et al (170). These authors identified myocardin in a subtractive hybridization 
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screen for gene targets of Nkx2.5 and went on to demonstrate that Nkx2.5 could transactivate 
myocardin expression by binding to an Nkx2.5 responsive element (NKE) within the 
myocardin promoter. Further examination of the myocardin promoter will certainly be 
important for identifying the mechanisms by which myocardin gene expression is regulated. 
Moreover, it will be equally important to determine whether myocardin activity (as opposed 
to myocardin expression) is modulated by agonist-induced changes in post-translational 
modification. 
REGULATION OF MRTF ACTIVITY 
Miralles et al were the first to show that MRTF-A’s ability to stimulate transcription 
was regulated by RhoA-dependent signaling (104). These authors demonstrated in NIH3T3 
cells that MRTF-A resides nearly exclusively in the cytoplasm in serum-starved cells, and 
that MRTF-A translocated to the nucleus upon stimulation by serum or other interventions 
that increased RhoA activity or actin polymerization (Fig 1.5).  The RPEL domains in 
MRTF-A’s N-terminus (see figure 1.1 for domain map) were shown to interact directly with 
G-actin (126), and deletion or mutation of RPEL domains 2 and 3 resulted in MRTF-A 
variants that were constitutively nuclear (104). Taken together these results indicated that in 
un-stimulated cells, MRTF-A is retained in the cytoplasm through an interaction with G-actin 
and that RhoA-induced depletion of the G-actin pool frees MRTF-A to enter the nucleus 
where it can stimulate SRF-dependent transcription.  The C-terminal and Q-rich regions were 
also implicated in MRTF-A localization (104). These domains were not important for RhoA 
mediated nuclear import but possibly other aspects of MRTF-A localization such as nuclear 
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retention or nuclear export.  Interestingly, myocardin has a slight mismatch in RPEL domain 
2 which may explain why myocardin is constitutively nuclear. 
When taken together with our observations that RhoA was an important determinant 
of SMC-specific gene expression and that MRTF-A protein is expressed in rat aortic SMC 
cultures (88), we and others hypothesized that MRTFA may serve as an important link 
between the extrinsic cues that regulate SMC function and the transcriptional machinery that 
ultimately determines SMC phenotype (35). Indeed, Cen et al reported that DN MRTF-A 
could inhibit the effects of constitutively active RhoAV14 on SRF-dependent promoter 
activity in HeLa cells (16). Similarly, our laboratory demonstrated that dominant negative 
N19RhoA could inhibit MRTF-A transactivation and that DN variants of MRTF-A could 
inhibit S1P-induced activation of SMC-specific gene expression, an effect that is dependent 
upon activation of RhoA (88). Other studies from our laboratory have further demonstrated 
that the actin remodeling-dependent effects of RhoA on MRTF-A activity are mediated at 
least in part by the formin proteins mDia1 and mDia2, and that inhibition of these actin-
polymerizing proteins also inhibits MRTF-A activity (155).  
Several studies from other laboratories have suggested that the regulation of MRTF-A 
localization may be more complicated than originally described.  Du et al reported that over-
expressed MKL-1 was constitutively nuclear in rat aortic SMC (35).  Selvaraj et al also failed 
to observe any increase in nuclear localization of MKL-1 upon serum stimulation of NIH3T3 
or HeLa cells (142). Although differences in MRTF-A detection (i.e endogenous vs epitope, 
tagged vs EGFP fusion), species differences, or slight differences in culture conditions could 
explain these discrepancies, there are probably cell-type or species-specific differences in the 
regulation of MRTF-A localization. Furthermore, the differences seen in these model 
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systems may reflect inherent differences in RhoA signaling in these cell-types. Many 
different environmental factors affect RhoA signaling (see (51) for a review), making it 
likely that multiple environmental cues are important for regulating MRTF-A localization, 
and it is possible that specific cues may have different roles in different cell types. 
Less has been reported regarding the regulation of MRTF-B activity, but it appears 
that MRTF-B is also regulated by RhoA signaling. Olson and associates first demonstrated 
this, showing that both MRTF-A and MRTF-B nuclear localization were increased upon 
serum stimulation (a known activator of RhoA). These authors demonstrated that over-
expression of the protein striated muscle activator of Rho signaling (STARS) led to increases 
in MRTF/SRF/CArG-dependent gene expression. STARS was shown to promote release of 
MRTFs from actin pools in a manner dependent upon its actin-binding domain (72).  
Important differences in the regulation of MRTF-A and MRTF-B localization by 
RhoA have also been noted. Zhoa et al used an in vitro force-induced model of RhoA 
activation to study the role of Rho-kinase in the regulation of SM α-actin gene expression in 
myofibroblasts. These authors observed in fibroblasts that following activation of the RhoA 
pathway by force, MRTF-A translocated to the nucleus while MRTF-B did not (192). A 
potentially important difference between MRTF-A and MRTF-B is the presence of a 71 AA 
N-terminal region in MRTF-B that does not seem to be present in MRTF-A (although the 
precise translational start site of MRTF-A is not completely clear) (Fig 1.4). In addition, the 
MRTF-B message contains a long 3’UT that is not found in myocardin or MRTF-A, and this 
region contains several binding elements that may regulate MRTF-B translation.  
Recent studies have identified a single MRTF (DMRTF) in drosophila that regulates 
tracheal branching and cell migration (52, 151). Interestingly, nuclear accumulation of 
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DMRTF is stimulated by increased cell tension, an environmental parameter that is known to 
increase RhoA activity (151). These findings suggest that not only is the MRTF-SRF 
interaction highly conserved throughout evolution, but that the regulation of MRTF-A 
translocation by RhoA may be as well.  
The precise mechanisms that regulate MRTF nuclear/cytoplasmic translocation are 
somewhat unclear. In the simplest model proposed by Treisman and colleagues, G-actin 
binding to the RPEL domain could mask a nuclear localization signal that is exposed when 
G-actin pools are reduced following RhoA stimulation. However, the two basic domains (B1 
and B2) that are required for RhoA mediated nuclear translocation do not seem to function as 
nuclear localization sequences in that they do not promote nuclear localization when linked 
to a heterologous protein (104). Furthermore, Posern et al has described a mutant actin that 
can stimulate MRTF-A nuclear translocation independent of its effects on actin treadmilling 
suggesting a more direct mechanism by which actin may stimulate MRTF-A translocation 
(126). Interestingly, in NIH3T3 and C2C12 cells, MRTF-A’s C-terminus is S/T 
phosphorylated upon serum treatment (104). While this phosphorylation does not seem to be 
involved in RhoA-dependent nuclear import, it may be important for the C-terminus’ role in 
mediating nuclear retention or export or may have other effects on MRTF-A function.  
Over-expression of MRTFs, even in cells that already express these proteins 
endogenously, has been shown to strongly activate SRF-dependent gene expression (16, 35, 
88, 142). It follows that regulation of myocardin factor expression, either at the mRNA or 
protein level, may be an important mode of regulating their activities. However, no studies to 
date have been published identifying mechanisms that regulate MRTF expression. Two 
separate studies from our laboratory, detailed here in later chapters, have each examined this 
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topic in detail. In the first we demonstrate that many of the mechanisms known to stimulate 
myocardin factor activity do not affect their expression at the mRNA level, and in the second 
we provide the first lines of evidence implicating the proteasome as an important determinant 
of myocardin factor protein expression and activity.  
THE UBIQUITIN-PROTEASOME SYSTEM 
The ubiquitin-proteasome system (UPS) is the major regulator of non-lysosomal 
protein degradation within the cell. Efficient degradation of misfolded and malfunctioning 
proteins is critical for proper cellular function. The proteasome has been directly implicated 
in a wide array of processes and pathways including cellular metabolism, immune 
surveillance, apoptosis, signal transduction, gene transcription, proliferation, and 
differentiation (29). Despite UPS involvement in such varied cellular activities, UPS-
mediated protein degradation is highly specific and tightly regulated. Improper proteasomal 
function has been implicated in the pathogenesis of multiple human diseases, including 
cancer, atherosclerosis and congestive heart failure (98, 123, 171). A brief description of this 
system is included below. 
Protein ubiquitination occurs in a three-step process, each relying on a specific class 
of enzyme (E1-E3) (Fig 1.6A). First, an E1 ubiquitin activating enzyme binds free ubiquitin 
in an ATP-dependent manner. The ubiquitin molecule is then transferred to an E2 ubiquitin 
conjugating enzyme in a manner independent of ATP. In the third and final step of the 
process, an E3 ubiquitin ligase recognizes the substrate to be ubiquitinated and transfers the 
ubiquitin molecule from E2 to the substrate (162). In this manner, it is the E3 ligase that 
confers specificity in ubiquitination. Accordingly, there are a great many more E3 ligases 
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than there are E2 conjugating enzymes, and there are very few E1 ubiquitin activating 
enzymes.  
E3 ubiquitin ligases belong to one of two groups, divided by their mode of substrate 
ubiquitination. The first of these groups consists of the RING (really interesting new gene) 
domain-containing proteins and the structurally similar U-box proteins. These E3 ligases 
bind to ubiquitin carrying E2 ubiquitin conjugating enzymes and to their substrates 
simultaneously, and facilitate shape changes that lead to transfer of ubiquitin to the substrate. 
The second group is the HECT (homologous to E6-associated protein C terminus) domain 
proteins. These E3 ligases bind ubiquitin carrying E2 ubiquitin conjugating enzymes, and 
transfer the ubiquitin molecule to their own HECT domain. The ubiquitin molecule is 
transferred to the substrate in a second step. Regardless of the type of E3 enzyme used, the 
result is the formation of a covalent bond between a lysine residue of the ubiquitin molecule 
and a lysine residue of the substrate, usually located at its N-terminus. Poly-ubiquitin chains 
are often formed next, and are accomplished by E4 enzymes that catalyze the formation of 
similar covalent bonds between individual ubiquitin molecules (171). 
Mono-ubiquitination of substrates has been demonstrated to result in various effects, 
including alterations in protein activity and localization, while poly-ubiquitination most often 
leads to ATP-dependent degradation via the 26S proteasome (Fig 1.6B)(113). The 26S 
proteasome contains three main subunits. Two outer 19S subunits allow for recognition of 
poly-ubiquitinated substrates, and sit on either side of a central barrel-shaped 20S subunit. 
The 19S subunits also harbor ATP activity at their bases that is used to unfold and de-
ubiquitinate proteins as they enter the central tunnel of the proteasome. The 20S subunit is 
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comprised of 4 rings (2 outer α and 2 inner β rings), and as proteins pass through this barrel 
shaped structure, they are degraded by the proteolytic β-ring core (171).  
OBJECTIVES OF THIS DISSERTATION RESEARCH  
A better understanding of SMC differentiation and phenotypic modulation depends 
upon further description of the mechanisms that regulate SMC-specific transcription.  The 
central role of SRF and myocardin factors in this regulatory pathway makes them excellent 
targets for investigation. The overall objectives of this dissertation research were to (1) 
determine the extent to which myocardin factors MRTF-A and MRTF-B contribute to SMC-
specific gene expression and to identify molecular mechanisms that regulate MRTF activity, 
(2) identify novel members of the transcriptional complex present at the promoters of SMC 
differentiation marker genes using a yeast-2-hybrid screen approach, and to define the role of 
identified factors in the regulation of SRF-dependent SMC gene transcription, and (3) 
characterize the role of the E3 ubiquitin ligase muscle specific ring finger 3 in the regulation 
of myocardin factor activity and protein stability. 
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ABSTRACT 
Based upon our previous studies on RhoA signaling in smooth muscle cells (SMC), 
we hypothesized that RhoA-mediated nuclear trans-localization of the Myocardin-Related 
Transcription Factors (MRTFs) was important for regulating SMC phenotype.  MRTF-A 
protein and MRTF-B message were detected in aortic SMC and in many adult mouse organs 
that contain a large SMC component. Both MRTFs up-regulated SMC-specific promoter 
activity as well as endogenous SM22α expression in multipotential 10T1/2 cells, although to 
a lesser extent than myocardin. We used EGFP fusion proteins to demonstrate that the 
 38 
myocardin factors have dramatically different localization patterns and that the stimulation of 
SMC-specific transcription by certain RhoA-dependent agonists was likely mediated by 
increased nuclear translocation of the MRTFs. Importantly, a dominant negative form of 
MRTF-A (ΔB1/B2) that traps endogenous MRTFs in the cytoplasm inhibited the SM α-actin, 
SM22α, and SM MHC promoters in SMC and attenuated the effects of S1P and TGF-β on 
SMC-specific transcription. Our data confirmed the importance of the N-terminal RPEL 
domains for regulating MRTF localization, but our analysis of MRTF-A/myocardin chimeras 
and myocardin RPEL2 mutations indicated that the myocardin B1/B2 region can over-ride 
this signal.  Gel shift assays demonstrated that myocardin factor activity correlated well with 
ternary complex formation at the SM α-actin CArGs, and that MRTF-SRF interactions were 
partially dependent upon CArG sequence. Taken together our results indicate that the 
MRTFs regulate SMC-specific gene expression in at least some SMC sub-types, and that 
regulation of MRTF nuclear localization may be important for the effects of selected agonists 
on SMC phenotype. 
INTRODUCTION 
 Vascular smooth muscle cell (SMC) differentiation is a very important process during 
vasculogenesis and angiogenesis, and it is recognized that alterations in SMC phenotype play 
a role in the progression of several prominent cardiovascular disease states including 
atherosclerosis, hypertension, and restenosis (122, 138). The identification of the 
transcription factors involved in this process has been complicated by the lack of terminal 
differentiation in this cell-type and the fact that SMC derive from multiple locations 
including local mesoderm, cardiac neural crest, the proepicardial organ, and possibly 
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circulating stem cells (see (122) for review).  A completely SMC-specific transcription factor 
has yet to be described, and evidence suggests that SMC differentiation may be regulated by 
interactions between multiple transcription factors with overlapping expression patterns (15, 
19, 48).  We and others have shown that the SMC differentiation marker genes are regulated 
by serum response factor (SRF), a MADS Box transcription factor that binds to conserved 
CArG boxes found in nearly all of the SMC marker gene promoters (55, 79, 91, 93, 95, 100).  
Since SRF is ubiquitously expressed and regulates a variety of other muscle-specific genes as 
well as early response genes, c-fos and egr-1 (11, 22, 152, 168, 173), it is clear that additional 
mechanisms are involved. 
 An important breakthrough in the study of the molecular mechanisms that regulate 
SMC differentiation was the discovery of the myocardin family of SRF co-factors by Wang 
et al (175). The founding member of this family, myocardin, is selectively expressed in the 
heart and SMC and very powerfully transactivates SMC differentiation marker gene 
expression by physically interacting with SRF. Importantly, genetic deletion of myocardin 
resulted in embryonic lethality at E10.5 due, at least in part, to failure of SMC differentiation 
in the mesodermal cells surrounding the descending aorta (82). In more recent studies, Pipes 
et al used a chimeric mouse model to demonstrate that myocardin -/- cells could populate the 
developing aorta suggesting that myocardin-independent mechanisms are likely to be 
important for SMC differentiation (125). 
 Two Myocardin-Related Transcription Factors, MRTF-A/MKL-1 and MRTF-
B/MKL-2, have been identified that have similar transcriptional activity to myocardin. These 
factors are thought to be expressed more widely, and their role in regulating cell-type-
specific gene regulation is much less clear.  MKL-1 message is expressed strongly in a 
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variety of human tissues that have a large SMC component including the aorta and bladder, 
and we and others have detected MRTF-A/MKL-1 protein in multiple SMC lines, including 
primary rat aortic SMC, A7R5, A10, and PAC-1 as well as mouse embryonic stem cells and 
multipotential 10T1/2 cells (35, 88).  Over-expression of MRTF-A/MKL-1 strongly up-
regulated several muscle-specific promoters in a variety of cell-types and importantly was 
sufficient to activate endogenous expression of SMC differentiation marker genes in ES 
cells. MRTF-B was originally shown to have little effect on CArG-dependent transcription 
(176). However, its human homologue, MKL-2, strongly activated the ANF, SM22α, and 
SM α-actin promoters in HeLa cells (142). Since these proteins share greater than 80% 
homology, the reason for this discrepancy is currently unknown.  Two separate groups have 
recently shown that genetic disruption of MRTF-B led to a lethal defect in pharyngeal arch 
remodeling and that this phenotype was accompanied by a failure of SMC differentiation of 
the cardiac neural crest cells that populate the cardiac outflow tract (78, 117).  Interestingly, 
both Li et al and Sun et al have shown that MRTF-A knockout females have a nursing defect 
that is accompanied by a loss of SMC differentiation marker gene expression that normally 
occurs in the myoepithelial layer of the mammary gland during lactation (81, 156).   
 Identification of the mechanisms that regulate the myocardin transcription factors will 
be very important for our understanding of their role in cell-type-specific gene regulation. 
Miralles et al were the first to demonstrate that the activity of MRTF-A was regulated by 
RhoA-dependent signaling (104). These authors demonstrated in NIH3T3 cells that MRTF-A 
resided nearly exclusively in the cytoplasm in serum-starved cells, that MRTF-A translocated 
to the nucleus upon serum stimulation, and that this process was regulated by RhoA-
dependent changes in actin polymerization.  The RPEL domains in MRTF-A’s N-terminus 
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were shown to bind to G-actin (126), and this interaction was shown to be important for 
retaining MRTF-A in the cytoplasm. A recent study indicated that MRTF-B localization may 
be regulated by the same mechanism (72). Interestingly, myocardin is constitutively nuclear, 
and it has been suggested that lack of conservation in myocardin’s second RPEL domain may 
inhibit cytoplasmic retention (104).  Several groups have reported somewhat contrasting 
results on MRTF-A localization (35, 142). For example, Du et al reported that in primary rat 
aortic SMC, MRTF-A/MKL-1 was constitutively nuclear in serum starved cells or in the 
presence of dominant negative RhoA. In addition, Selvarej et al did not observe nuclear 
translocation of MKL-1 upon serum stimulation of NIH 3T3 and HeLa cells (142). The 
reason for these discrepancies is unknown.  
We have previously shown that RhoA is an important determinant of SMC 
differentiation marker gene expression and that MRTF-A was required for the up-regulation 
of SMC-specific transcription observed upon treatment of aortic SMC with the strong RhoA 
agonist, sphingosine 1-phosphate (S1P) (88, 92).  The goals of the present study were to 
determine the contributions of the MRTFs to SMC-specific gene regulation, to test whether 
regulation of MRTF nuclear localization is an important signaling mechanism for controlling 
SMC-specific transcription and to further characterize the differences between the three 
myocardin transcription factors. 
MATERIALS AND METHODS 
Plasmids and Proteins - Myocardin, MRTF-A and MRTF-B plasmids were a 
generous gift of Da-Zhi Wang (University of North Carolina, Chapel Hill, NC). MRTF 
deletions lacking the N-terminal RPEL domains were created by PCR. The dominant 
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negative ΔB1/B2 MRTF-A was a generous gift of Richard Treisman (Cancer UK, London) 
and has been described previously (104).  MRTF-A/myocardin chimeras that fused N-
terminal fragments of MRTF-A to C-terminal fragments of myocardin were made by PCR. 
An exogenous XhoI restriction site (that codes LE) was inserted at the MRTF-A/myocardin 
junction to facilitate cloning, and junction sites were placed in regions of low homology. 
More details on the MRTF-A/myocardin chimeras can be found in figure 2.3 and are 
available upon request. The myocardin double mutation S72P, S76E that restored RPEL2 
was made using the QuikChange method (Stratagene). All myocardin factors were subcloned 
into a flag-tagged pcDNA3.1 and/or an EGFP expression vectors. 
Cell Culture, Transient Transfections, and Reporter Assays – SMCs from rat thoracic 
aorta were isolated, cultured, and transfected as previously described (91, 147).  In short, 
cells were maintained in 24 well plates in 10% serum and were transfected 24 h after plating 
at 70-80% confluency using the transfection reagent, Superfect (Qiagen), as per protocol.  
The SM22α promoter (from –450 to +88), SM α-actin promoters (from -2560 to +2784), SM 
MHC promoter (from –4200 to + 11600), and c-fos promoter (from -356 to +109) used in 
this study have been previously described (80, 93, 94). In some experiments myocardin, 
MRTF-A, MRTF-B, or variants thereof were co-transfected along with the promoter-
luciferase constructs.  
Prior to agonist treatments, SMC were placed in serum free media for 24 h while 
10T1/2 cells were placed in 0.2% charcoal treated serum (to remove serum lipids).  Cells 
were treated with S1P (1uM), 10% serum, TGF-β (1ng/ml), PDGF-BB (20ng/ml), and 
luciferase assays were performed after 24 h.  In some experiments the Rho-kinase inhibitor, 
Y-27632 (10 uM), was added 15 minutes prior to addition of agonist. The S1P used in these 
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experiments was obtained from Matreya and was maintained in 4 mg/ml fatty-acid free BSA 
which was used as a vehicle control.  Relative promoter activities are expressed as the means 
+/- standard error computed from a set of at least three separate transfection experiments.  
We did not co-transfect a viral promoter/Lac Z construct as a control for transfection 
efficiency since we have previously shown that such constructs exhibit unknown and variable 
squelching effects on the SM-specific promoters presumably due to competition for common 
transcription factors (147).  Moreover, we have found that inclusion of such controls are 
unnecessary in that variations in transfection efficiency between independent experimental 
samples is routinely very small (<10%)(147). 
Analysis of MRTF expression - Adult C57/Black6 mice were sacrificed, and blood 
was removed by perfusing phosphate-buffered saline through the vasculature via a puncture 
of the left ventricle. Tissues were excised and homogenized in RIPA buffer plus inhibitors by 
sonication. Lysates were clarified by centrifugation and protein concentrations were 
determined using BCA protein assay (Pierce). 150ug total protein from each tissue lysate was 
run on an 8% SDS polyacrylamide gel, and subsequently transferred to nitrocellulose. 
MRTF-A was detected using MRTF-A antiserum generously provided by Richard Treisman 
(Cancer Research UK, London). In vitro translated MRTF-A was prepared using Promega's 
TNT T7 Coupled Reticulocyte Lysate System and was run along side the lysates as a positive 
control.  Semi-quantitative PCR was used to measure MRTF-B expression. In brief, RNA 
was prepared from cell and tissues as above using Trizol Reagent (Invitrogen), and quantified 
by Ribogreen Assay (Molecular Probes). cDNA was generated with the iScript cDNA 
synthesis kit (Biorad) using 1ug of RNA per manufacturer’s protocol. The following exon 
spanning primers were used for amplification reactions: MRTF-B, 5’-atgaggaagccatcaagcag-
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3’ and 5’-atctgctgactgtgcaca-3’; GAPDH, 5’-atgggtgtgaaccacgaagaa -3’ and 5’-
ggcatggactgtggtcatga-3’.  
Visualization of myocardin factor localization – The myocardin factors were 
subcloned into the pEGFP-C3 vector (Clontech). SMC and 10T1/2 were transfected with 
fusion protein plasmids as described above, maintained in 10% serum overnight, and then 
held in serum free media for 24 h.  After addition of agonist, myocardin factor localization 
was monitored in real time on an inverted fluorescent microscope, and images were taken at 
5 min intervals for 80 min using a Spot digital camera.  Micrographs were converted into 
time-lapse movies using Isee imaging software and QuickTime. To quantify localization in 
the entire cell population, cells were fixed after 80 minutes of treatment in 4% 
paraformaldehyde, and localization was scored into 3 separate categories: nuclear, diffuse, 
and cytoplasmic. 
Gel shift analyses - SRF and flag-tagged myocardin factors were translated in vitro 
using the Promega T7 TnT kit.  Binding reactions contained 1 uL SRF, 2 uL of myocardin 
factor, 20,000 cpms of a P32-labeled oligonucleotide probe containing CArGA, CArGB or the 
intronic CArG from the rat SM α-actin promoter, 0.20 ug dIdC in binding buffer (10 mM 
Tris, pH 7.5, 50mM NaCl, 100 mM KCl, 1mM DTT, 1mM EDTA, 5% glycerol).  Reactions 
were incubated for 30 min before loading on non-denaturing 4% polyacrylamide gel that was 
pre-run at 170V for 1hr. Electrophoresis was performed at 170V in 0.25X TBE (45 mM Tris 
Borate, 1 mM EDTA).  Gels were dried and exposed to film for 24-72 h at -80°C. For 
supershift studies, 1 µl of M2 Flag antibody (Sigma) was added after 20 min of incubation. 
RESULTS 
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 MRTF-A and MRTF-B were expressed in aortic SMC and many SM-containing 
tissues. Previous studies have demonstrated that the MRTFs are expressed more widely than 
myocardin (176). However, MRTF-A message expression is extremely high in the human 
aorta and fairly high in bladder, stomach, intestine, and in many SMC or SMC-like cell lines 
including primary rat aortic SMC, A10, PAC-1, and 10T1/2 (35) suggesting that it may have 
an important role in SMC. To get a better idea of MRTF-A protein expression in adult mouse 
SMC-containing tissues, we performed Western analysis. Results shown in Figure 2.1 
demonstrate that MRTF-A levels were high in aorta, bladder, lung, and uterus and in rat 
aortic and A7r5 SMC cultures. The size of immunoreactive bands varied slightly between 
tissues indicating that MRTF-A may be post-translationally modified or processed in a cell-
type-specific manner. Due to the lack of a suitable MRTF-B antibody, we used semi-
quantitative RT PCR to measure MRTF-B expression in adult mouse SMC-containing 
tissues. Figure 2.1b demonstrates that MRTF-B message was more evenly distributed, but 
was relatively high in aorta, lung, stomach, liver, and rat aortic SMC cultures. 
The MRTFs regulated SMC differentiation marker gene expression. Myocardin 
has been shown to regulate SMC differentiation(36, 82, 189), but the role played by the 
MRTFs in this process is less clear. To directly compare activation of SMC-specific gene 
expression by all three myocardin factors, we expressed them in multi-potential 10T1/2 cells.  
This cell line is a very useful and consistent model for studying the regulation of SMC-
specific transcription because many endogenous SMC-specific differentiation marker genes 
including SM α-actin, SM22α, and calponin can be induced by agonists such as TGF-β or 
sphingosine-1 phosphate (62, 88).  As shown in figure 2.2, all three of the myocardin factors 
transactivated the SM α-actin and SM22α promoters and stimulated the endogenous 
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expression of SM22α. However, transactivation by myocardin was significantly greater than 
that induced by MRTF-B and in most instances greater than that induced by MRTF-A even 
though these transcription factors were expressed at similar levels.  Our data also support 
previous studies that demonstrated that the N-terminal actin-binding region of both MRTF-A 
and MRTF-B had inhibitory effects on their activities.  
MRTF activity was regulated by nuclear localization.  MRTF-A nuclear 
localization has been shown to be regulated by RhoA signaling (88, 104) and we hypothesize 
that changes in MRTF nuclear localization may help explain the effects of certain 
environmental cues on SMC-specific transcription. To begin to test this, we constructed 
EGFP fusion proteins so that we could monitor myocardin factor localization in real time.  
Fusion protein expression was confirmed by Western blot using an anti-EGFP antibody and 
results from co-transfection experiments demonstrated that these fusion proteins significantly 
activated the SM α-actin promoter suggesting that the EGFP moiety did not dramatically 
disrupt myocardin protein function (data not shown). Initially, 10T1/2 cells were serum 
starved for 24 h, fixed, and scored for localization into 3 separate categories: nuclear, diffuse, 
and cytoplasmic. Myocardin localization was constitutively nuclear even after prolonged 
serum deprivation while MRTF-B localization was nearly completely cytoplasmic under the 
same conditions (figure 2.3). Interestingly, MRTF-A could localize to the nucleus or 
cytoplasm but was often found in a more diffuse pattern. In addition, neighboring cells with 
dramatically different MRTF-A localization patterns were frequently observed.  Since it has 
been shown that RhoA activity is down regulated in confluent SMC and other cell-types 
(115, 191), we also tested whether cell density could affect MRTF-A localization. As shown 
in figure 2.3B, the percentage of cells containing MRTF-A exclusively in the nucleus was 
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significantly inhibited in confluent cells versus cells that were 50-70% confluent.  Because 
these localization patterns correlated fairly well with the relative activities of the myocardin 
factors shown (figure 2.2), we tested whether serum starvation had differential effects on 
myocardin and MRTF-A activity.  Results shown in figure 2.3C demonstrate that 
transactivation by myocardin was unaffected by serum withdrawal. In contrast, MRTF-A 
activity was reduced by approximately 70%, a result in excellent agreement with previous 
studies (104).   
MRTF localization was regulated by specific agonists. We also monitored the 
localization of MRTF-A and MRTF-B in real time following treatment with several different 
agonists that have been shown to have variable effects on SMC differentiation marker gene 
expression including 10% serum, S1P, TGF-β, and PDGF-BB. In cells that contained MRTF-
A in the cytoplasm, stimulation of cells with 10% serum or S1P (both strong activators of 
RhoA signaling) caused MRTF-A to translocate to the nucleus within a time span of about 
45-60 min (Fig 2.4A). To better quantify the effects of these agonists, we fixed cells after 80 
minutes and scored for localization. Results shown in figure 2.4B demonstrate that serum or 
S1P treatment significantly increased the number of cells that exhibited nuclear localization 
of the MRTFs and significantly decreased the number of cells exhibiting cytoplasmic or 
diffuse localization. Pre-treatment of cells with the Rho-kinase inhibitor, Y-27632, 
completely inhibited the effects of S1P on nuclear translocalization of MRTF-A.  Somewhat 
surprisingly, Y-27632 did not seem to cause MRTF-A that was already nuclear (~ 20% of 
cells) to translocate to the cytopjlasm during the time frame of these studies suggesting that 
nuclear retention and/or export are regulated by a separate mechanism. Treatment of cells 
with TGF-β slightly increased MRTF-A nuclear localization but had no 
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effect on MRTF-B.  PDGF-BB had no effect on localization of either of the MRTFs. Parallel 
transfection experiments demonstrated that the effects of S1P, serum, and PDGF-BB on 
MRTF localization correlated well with their abilities to stimulate SM α-actin promoter 
activity in this model system (figure 2.4C). In contrast, although TGF-β had only minor 
effects on MRTF-A nuclear translocation at 80 min, it strongly stimulated SM α-actin 
promoter activity. Analysis of MRTF localization in TGF-β treated cells at 3h, 6h, and 24h 
demonstrated no further changes in MRTF localization.  
 As shown in figure 2.5, MRTF nuclear localization in SMC was slightly different. 
Under serum starved conditions, a significantly greater proportion of SMC contained MRTFs 
in the nucleus or in the diffuse pattern instead of exclusively in the cytoplasm. Also, S1P- 
and serum-induced nuclear translocation occurred much more quickly (~10 min vs ~60 min) 
(figure 2.5A).   
MRTF nuclear translocation was required for SMC-specific transcription. 
Results presented so far indicate that MRTF-A and MRTF-B are expressed in aortic SMC, 
can activate SMC-specific transcription when over-expressed, and show increased nuclear 
localization upon stimulation with S1P or serum. To test whether nuclear localization is 
important for SMC differentiation marker gene expression in SMC, we used a dominant 
negative generated by Miralles et al that contains deletions to two N-terminal basic domains 
that were shown to be required for nuclear localization of MRTF-A (ΔB1/B2) (104).  These 
authors showed that ΔB1/B2 MRTF-A trapped endogenous MRTF-A in the cytoplasm 
through dimerization, thus inhibiting its activity as a transcription factor (104). Indeed, 
ΔB1/B2 MRTF-A acted as a dominant negative in our model system attenuating, in a dose-
dependent manner, the increase in SM α-actin activity mediated by over expression of Wt 
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MRTF-A (figure 2.6A). Importantly, ΔB1/B2 MRTF-A inhibited the activity of the SM22α, 
SM α-actin, and SM MHC promoters in SMC indicating that MRTF activity is important for 
regulating SMC differentiation marker gene expression (figure 2.6B). ΔB1/B2 MRTF-A also 
inhibited the up-regulation of SM22α and SM α-actin promoter activity in 10T1/2 cells 
treated with sphingosine-1-phosphate (S1P) or TGF-β (figure 2.6C,D). Interestingly, ΔB1/B2 
significantly augmented activation of the c-fos promoter by S1P and TGF-β in this model 
(figure 2.6E). Taken together, these data indicate that nuclear translocation of the MRTFs 
regulates SMC-specific transcription and may serve as an important link between the 
extrinsic cues that regulate SMC function and the transcriptional machinery that ultimately 
determines SMC phenotype. 
Myocardin factor nuclear localization was regulated by N-terminal-dependent 
and N-terminal-independent mechanisms.  Results shown in Figure 2.2 demonstrate that 
the N-terminal actin binding domains of MRTF-A and MRTF-B inhibit their activity. Studies 
have shown that the N-terminal MRTF RPEL motifs bind non-polymerized G-actin to trap 
the MRTFs in the cytoplasm and that RhoA-dependent actin polymerization reduces the G-
actin pool to release this inhibitory mechanism (126).  Interestingly, although the removal of 
the N-terminal RPEL domains increased MRTF activity, the ΔN MRTFs (especially ΔN 
MRTF-B) were still less active than myocardin suggesting that additional regulatory 
mechanisms may affect their nuclear localization or activity. Further supporting this idea was 
our finding that ΔN MRTF-B did not localize exclusively to the nucleus under serum free 
conditions and was found in a diffuse pattern in about 50% of the cells examined. 
To further identify regions in the myocardin factors that govern their nuclear 
localization we made a series of chimeric molecules that replaced N-terminal portions of 
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myocardin with those of MRTF-A. The myocardin used for these experiments was the 935 
amino acid form that contains the entire N-terminus. Although the myocardin N-terminal 
region is highly homologous to that of the MRTFs, this form of myocardin is still 
constitutively nuclear. The chimeric constructs that were generated are depicted in Figure 
2.7A along with the percentage of cells that showed nuclear localization for each chimera. 
Interestingly, MRTF-A sequences up to the second RPEL domain did not significantly affect 
localization of myocardin while replacement with an MRTF-A sequence that also included 
the second basic (B2) and third RPEL domains decreased nuclear localization to 57%. 
Another large decrease in nuclear localization (to 33%) was seen upon inclusion of an 
MRTF-A sequence that contained the region containing basic domain 1 (B1). Further 
inclusion of C-terminal MRTF-A sequences gradually reduced chimera localization to that of 
MRTF-A (20%). 
It has been suggested that variations in myocardin that disrupt the actin-binding 
RPEL motif in RPEL domain 2 may be responsible for the constitutive nuclear localization 
of full-length myocardin. To directly test this hypothesis, we mutated the divergent 
sequences in RPEL2 back to a consensus RPEL domain and monitored nuclear localization 
and transcriptional activity of the mutated protein (see figure 2.7B). This myocardin RPEL2 
mutant (MC-R2) localized to the nucleus in 100% of the cells examined and had 
transcriptional activity that was identical to that of Wt myocardin (data not shown). 
Differential SRF binding also regulates myocardin factor activity. Our results 
suggest that differential nuclear localization explains, at least in part, the differences in 
myocardin factor activity observed in these studies. However, once in the nucleus, myocardin 
factor activity may also be regulated by differential binding to SRF.  To analyze myocardin 
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factor binding to SRF we performed electromobility shift assays. We also wanted to test 
whether variations in SRF binding contributed to interactions with specific myocardin 
factors. Thus, we used the three SM α-actin CArG elements (A, B, and intronic) that have 
dramatically different abilities to bind SRF due to G/C substitutions in their A/T rich regions.  
It is important to note that we used the ΔN versions of the MRTFs in this assay because actin 
binding to the full length MRTFs interferes with ternary complex formation in gel shift 
assays (104, 142)and data not shown). Results shown in figure 2.8 demonstrate that SRF 
binds to all three CArGs with varying affinity (intronic>B>>A). All three myocardin factors 
formed higher order complexes on the intronic CArG and could be super-shifted with anti-
flag antibody (lanes 13-15).  However, even though these SRF co-factors were present at 
equal amounts (see inset), myocardin binding to SRF was stronger than ΔN MRTF-A and 
much stronger than ΔN-MRTF-B. There were also differences in complex formation that 
were CArG-specific. For example, the intensity of the MRTF-A containing ternary complex 
(relative to SRF binding alone) was much less for the weaker CArGs than for the strong 
intronic CArG, a difference that was not apparent with myocardin (compare lane 7 to 11 and 
6 to 10). 
DISCUSSION 
Extensive evidence indicates that myocardin is an important regulator of SMC 
differentiation. While the role played by the MRTFs is less clear, several lines of evidence 
from the present study support their involvement in regulating SMC phenotype.  First, both 
MRTFs are expressed strongly in isolated SMC and in a variety of adult mouse tissues that 
contain a significant SMC component. While these studies obviously lack sufficient 
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resolution to determine whether the SMC within these organs express MRTF-A or MRTF-B, 
our results support a more in depth examination of MRTF expression by in situ or 
immunohistochemistry. Second, both MRTFs up-regulated SMC-specific promoter activity 
as well as endogenous SMC differentiation marker gene expression in 10T1/2 cells. 10T1/2 
cells do not express myocardin (189) indicating that either of the MRTFs was sufficient for 
this response. Third, a dominant negative form of MRTF-A (ΔB1/B2) significantly 
attenuated SMC-specific transcription in SMC. We and others have previously used 
dominant negative myocardin family variants that lack the transactivation domain to inhibit 
SMC-specific promoter activity. Importantly, however, these variants inhibit all three of the 
myocardin factors making it difficult to interpret experiments in SMC that express multiple 
members of this family (35). In the present study we used ΔB1/B2 MRTF-A to trap the 
endogenous MRTFs in the cytoplasm without affecting myocardin which is constitutively 
nuclear (175). Taken together, these results indicate that the MRTFs regulate SMC-specific 
transcription in SMC, perhaps in concert with myocardin.  The observations that myocardin 
and MRTF-A can associate directly though conserved leucine zipper motifs and that these 
motifs are required for full activity of these transcription factors supports this idea (35, 179).  
The phenotypes of the myocardin family member knockouts indicate that each 
member has essential non-redundant functions in the regulation of SMC differentiation 
marker gene expression (78, 81, 82, 117, 156). The early lethality associated with the 
myocardin and MRTF-B knockouts as well as the potential redundancy between these very 
similar transcription factors has made it difficult to determine whether the MRTFs are 
important for regulating SMC differentiation in the SMC sub-types where they are expressed. 
It is also unclear whether MRTFs are required for other aspects of SMC function that do not 
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directly involve specification such as the changes in gene expression that are known to occur 
during environmental stresses such as hypertension and atherosclerosis. Based upon the 
mammary myoepithelial defect observed in MRTF-A knock-out mice, the MRTFs may be 
responsible for the up-regulation of SMC marker gene expression that is observed in many 
SMC-like cells (i.e. myofibroblasts or mesangial cells) following injury (68, 177). 
Given the importance of the myocardin family for regulating SMC-specific 
transcription, the identification of the signaling mechanisms that regulate the expression 
and/or activities of these transcription factors will be very important to our understanding of 
the regulation of SMC phenotype. In our studies, agonist-induced up-regulation of SMC-
specific transcription did not correlate with increased expression of any of the myocardin 
factors ((88) and data not shown). Instead, our data indicated that RhoA-dependent regulation 
of MRTF nuclear localization was important and involved cytoplasmic retention of the 
MRTFs by a mechanism involving G-actin binding to the MRTF N-terminus.  Results 
obtained with the MRTF-A/myocardin chimeras and the myocardin RPEL2 domain mutant 
suggest that other regions are also important including basic region 1 (B1) and perhaps B2.  
These regions have already been implicated in nuclear import, and it is likely that a delicate 
balance exists between these nuclear localization and cytoplasmic retention signals. 
Since a number of extrinsic cues that regulate SMC differentiation also regulate 
RhoA activity, these studies indicate that regulation of MRTF nuclear localization may be an 
important mechanism by which environmental factors regulate SMC phenotype. The 
observation that ΔB1/B2 MRTF-A inhibited the induction of the SM22α and SM α-actin 
promoters by S1P and serum supports a role for MRTF nuclear translocation in this response, 
as does the direct correlation between the effects of S1P, serum, and PDGF-BB on promoter 
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activity and nuclear translocation of the MRTFs.  Interestingly, ΔB1/B2 MRTF-A actually 
increased c-fos promoter activity in S1P and TGF-β treated cells providing additional 
evidence that the myocardin factors differentially regulate SRF-dependent growth and SRF-
dependent differentiation. Wang et al have shown that myocardin and the ternary complex 
factors compete for SRF binding and the positive effects of ΔB1/B2 MRTF-A on the c-fos 
promoter would be consistent with this model (178). 
TGF-β was the strongest activator of SMC-specific transcription in these studies and 
has been shown to activate RhoA in some cell culture model systems (5, 24). The inhibitory 
effect of ΔB1/B2 MRTF-A on this response indicated that a basal level MRTF activity is 
required for TGF-β-induced up-regulation of SMC-specific promoter activity.  It is also 
possible that our inability to detect partial changes in MRTF localization following TGF-β 
treatment could explain these results. However, the observations that TGF-β had only minor 
effects on MRTF localization and that Y-27632 had little to no effect on TGF-β-induced SM 
α-actin promoter activity suggest that non RhoA-dependent mechanisms are more important.  
TGF-β’s effects on SMC-specific transcription are thought to be mediated by activation of 
the SMADs (SMADs 2 and 3 in particular) (129, 146, 149).  Our data would indicate while 
both pathways are essential for SMC differentiation marker gene expression, they probably 
act, at least to some extent, in parallel.  Interestingly, Chen et al demonstrated in Monc-1 
cells that Y-27632 inhibited TGF-β-induced SMC-specific gene expression and that 
dominant negative RhoA inhibited SMAD 2 and SMAD 3 nuclear localization (24). This 
same study showed that inhibition of RhoA in 10T1/2 cells (by DN-RhoA and C3 exotoxin) 
yielded more modest results suggesting that there are probably cell-type-specific differences 
in the importance of RhoA on TGF-β signaling.  Two recent studies have shown that 
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myocardin interacts directly with SMAD3 and SMAD1 to regulate transcription in smooth 
and cardiac muscle, respectively (13, 149). Therefore, it will be very important to further 
identify the mechanisms that integrate the RhoA and TGF-β signaling pathways. 
Because many environmental cues are known to affect RhoA activity (see (51) for a 
review), the regulation of MRTF localization is probably complicated by many cell-type-
specific and microenvironmental differences. Our observations that basal MRTF nuclear 
localization was higher in SMC than in 10T1/2 cells and that nuclear translocation occurred 
more quickly in SMC in response to treatment supports this idea. While our data suggest that 
cell confluency (a signal that inhibits RhoA signaling) attenuated MRTF nuclear localization, 
others have shown that application of cell tension (a signal that stimulates RhoA) promoted 
nuclear localization of drosophila MRTF (52, 151). The later findings suggest that not only is 
the MRTF-SRF interaction highly conserved throughout evolution, but that the regulation of 
MRTF translocation by RhoA may be as well. It is also possible that the contrasting results 
on MRTF localization that have been reported (35, 142) may reflect inherent differences in 
RhoA signaling between cell-types. 
Our gel shift assays demonstrated that the transcriptional activities of the myocardin 
factors are also regulated by their ability to interact with SRF. Even after removal of the 
inhibitory the N-terminal region, MRTF-SRF complexes were still much weaker than those 
formed with myocardin. As with nuclear localization, these differences correlated well with 
the relative activities of the myocardin factors suggesting that this parameter is also an 
important determinant of myocardin factor activity. Another interesting finding of our studies 
was that, relative to SRF binding, MRTF-A formed a more robust ternary complex at the 
intronic CArG than at CArGs A or B which was not the case for myocardin. Little is known 
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about the mechanisms by which the myocardin factors discriminate between SRF bound to 
the large number of CArG-dependent gene promoters, but these data suggest that variations 
in CArG sequence may be an important determinant. MRTF-A has been shown to 
preferentially interact with SRF at the vinculin and SRF promoters but not with SRF at the c-
fos or egr-1 promoters (104). While this difference may be due to known competition for 
SRF binding between the Elk-1 and the myocardin factors, slight differences in SRF 
conformation (or perhaps DNA bending) due to variations in CArG sequence may also play a 
role. In support of this, Zaromytidou et al have recently shown that MRTF-A co-
immunoprecipitated with SRF more strongly in the presence of a consensus CArG 
oligonucleotide than in the presence of a CArG that contained substitutions to the AT rich 
region (190).  It is clear that a better understanding of interactions between the different 
myocardin family members and specific SRF-CArG complexes will be important for 
delineating the role of the myocardin family in both cell-type-specific and gene-specific 
transcriptional regulation. 
In summary, results from the present study indicate that the MRTFs play an important 
role in the regulation of SMC differentiation marker gene expression in at least some SMC 
sub-types. Unlike myocardin, MRTF nuclear localization, and hence MRTF transcriptional 
activity, is regulated by agonists that activate RhoA, and we feel that this signaling pathway 
may be an important mechanism by which a variety of environmental cues regulate SMC-
specific transcription. Since SMC are known to maintain a significant level of plasticity even 
in adult animals, perhaps signaling mechanisms such as these have evolved as a mechanism 
by which SMC can quickly and reversibly alter their phenotype in response to environmental 
cues. 
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ABSTRACT 
Extensive evidence indicates that serum response factor (SRF) regulates muscle-specific 
gene expression and that the myocardin family SRF co-factors are critical for smooth muscle 
cell (SMC) differentiation. In a yeast-two-hybrid screen for novel SRF binding partners 
expressed in aortic SMC, we identified Four and a Half LIM domain protein 2 (FHL2) and 
confirmed this interaction by GST pull-down and co-immunoprecipitation assays.  FHL2 also 
interacted with all three myocardin factors and enhanced myocardin and MRTF-A-dependent 
transactivation of the SM α-actin, SM22, and cardiac ANF promoters in 10T1/2 cells. 
Expression of FHL2 increased myocardin and MRTF-A protein levels, and importantly, this 
effect was due to an increase in protein stability not due to an increase in myocardin factor 
mRNA expression. Treatment of cells with the proteasome inhibitors, MG132 and 
lactacystin, strongly up-regulated endogenous MRTF-A protein levels and resulted in a 
substantial increase in ubiquitin immunoreactivity in MRTF-A immunoprecipitants. 
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Interestingly, expression of FHL2 attenuated the effects of RhoA and MRTF-B on promoter 
activity perhaps through decreased MRTF-B nuclear localization or decreased SRF-CArG 
binding. Taken together, these data indicate that the myocardin factors are regulated by 
proteasome-mediated degradation and that FHL2 regulates SRF-dependent transcription by 
multiple mechanisms including stabilization of myocardin and MRTF-A. 
INTRODUCTION 
The MADS (MCM1, Agamous, Deficiens, SRF) box transcription factor, serum 
response factor (SRF), regulates cell-type-specific gene expression in cardiac, skeletal, and 
smooth muscle by binding to CArG elements present in most of the muscle differentiation 
marker gene promoters. Although SRF is highly expressed in all three muscle cell-types, it is 
a ubiquitously expressed factor that also regulates several early response growth genes 
including c-fos and egr-1 (11, 21, 152, 167, 173). Extensive evidence indicates that SRF 
activity is regulated mainly by its physical interaction with additional general and cell-type-
specific transcription factors.  The first SRF co-factors identified were the ternary complex 
factors (Elk-1, Sap-1, SAP-2/NET/ERP) that bind to SRF as well as to the Ets domain 
adjacent to the c-fos CArG following their phosphorylation by MAP kinase (see (12) for 
review).  SRF has also been shown to interact with cell-type specific factors such as MyoD 
and GATA-4 to regulate skeletal and cardiac muscle-specific gene expression, respectively 
(120, 144). 
The discovery of myocardin was a major advance in our understanding of the 
mechanisms that regulate SMC differentiation. This SRF co-factor is specifically expressed 
in cardiac and smooth muscle, powerfully stimulates SRF-dependent transcription in a 
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variety of cell-types, and is critical for SMC differentiation in vivo (23, 82, 175).  Two 
Myocardin-Related Transcription Factors, MRTF-A and MRTF-B were also described that 
have similar activities to that of myocardin (176). Although the MRTFs are expressed more 
widely, recent results in knock-out mice indicate that MRTF-B is required for SMC 
differentiation of cardiac neural crest cells while MRTF-A is required for SMC 
differentiation marker gene expression that normally occurs in the myoepithelial layer of the 
mammary gland during lactation (78, 81, 117, 156).  Interestingly, the myocardin factors are 
differentially regulated by sub-cellular localization, and our lab and others have shown that 
RhoA-dependent nuclear translocalization of the MRTFs is an important mechanism by 
which some extrinsic factors stimulate SMC-specific gene expression (35, 58, 88, 104). 
To identify additional factors involved in the regulation of SRF-dependent SMC-
specific transcription, we conducted a yeast-two-hybrid screen of a human aortic library 
using an amino terminal version of SRF (aa 1-201) as bait. Three of the clones identified 
coded for Four and a Half LIM domain-containing protein 2 (FHL2), a LIM-only protein that 
has been shown to be selectively expressed in the heart and SMC during development (26) 
(67) (158) and that functions as a transcriptional co-activator or co-repressor for a variety of 
transcription factors including the androgen receptor, cAMP-responsive element binding 
protein, AP-1, FOXO1, E4F1, and β-catenin (see (67) for review). Since FHL2 does not bind 
DNA directly, these effects are thought to be mediated by FHL2’s ability to facilitate protein-
protein interactions through its multiple LIM domains. 
In addition to its expression pattern during development, several features of FHL2 
function led us to examine its role in regulating SMC- and cardiac-specific transcription. 
First, Müller et al demonstrated that, like the MRTFs, FHL2 nuclear localization and 
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transactivation were dependent upon RhoA signaling (110). Second, Philippar et al used a 
genetic screen in SRF -/- ES cells to identify FHL2 as an SRF target gene whose up-
regulation correlated with increased SMC-specific gene expression in an ES cell model of 
SMC differentiation (124). These authors demonstrated that FHL2 interacted physically with 
SRF and that over-expression of FHL2 inhibited RhoA-dependent activation of SM22. 
Finally, Chang et al demonstrated that the SMC-specific LIM only proteins, CRP1 and 
CRP2, stimulated SMC-specific transcription by facilitating SRF’s interaction with GATA 
factors (18, 19). 
Our results confirm that FHL2 interacts with SRF, but we also demonstrate that FHL2 
binds directly to all three myocardin factors and has differential effects on their abilities to 
regulate cardiac and SMC-specific transcription. Importantly, FHL2 increased myocardin 
and MRTF-A transactivation and this effect may be due to protection of these factors from 
proteasomal degradation. 
MATERIALS AND METHODS 
Yeast 2-hybrid screen and plasmid construction - FHL2 was identified in a 
Matchmaker yeast two hybrid screen (Clontech) using the SRF N-terminus (aa 1-201) as bait. 
Full length FHL2 was subcloned into flag-pcDNA3 and PGEX4T1 vectors. Expression 
constructs for SRF, L63RhoA, Myocardin, MRTF-A, MRTF-B, and myocardin factor 
derivatives have been previously described (58, 88). The GST fusions, FHL2 0-2 and FHL2 
3/4, were generous gifts from Roland Schüle (University of Freiburg, Freiburg, Germany) 
and have been previously described (109). 
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Cell Culture, Transient Transfections, and Reporter Assays – The rat aortic SMC and 
10T1/2 cultures and the SMC-specific promoter assays used have been previously described 
(88).  In brief, cells were maintained in 10% serum media and transfected 24 h after plating 
at 70-80% confluency using LT-1 transfection reagent (Mirus) per protocol. Luciferase 
activity measurements were made 24 h post transfection. Luciferase activity was measured in 
relative light units (RLUs) and expressed as fold activity over empty vector. For harvesting 
of protein, cells were plated in 15cm dishes and lysed in RIPA + 0.5% triton.  
GST fusion pull-downs and co-immunoprecipitations - GST pull-down assays and co-
immunoprecipitations were performed as previously described (157). In brief, GST fusion 
proteins were purified from bacterial lysates using glutathione sepharose (Amersham 
Biosciences). Interacting proteins were in vitro translated and 35S labeled using the Promega 
TnT kit. Interacting complexes were pelleted by centrifugation and washed 2X in NETN 
solution and 1X in cold Tris-buffered saline.  For co-immunoprecipitations flag-FHL2 was 
expressed in 10T1/2 cells and immunoprecipitations were performed using anti-flag or anti-
SRF Abs. 
Semi-quantitative PCR - RNA was prepared from cell and tissue lysates using Trizol 
Reagent (Invitrogen) and was quantified by Ribogreen Assay (Molecular Probes). cDNA was 
generated from 1ug of RNA using in the iScript cDNA synthesis kit (Biorad). Exon spanning 
primers were used to amplify FHL2, myocardin, MRTF-A, MRTF-B and GAPDH 
(sequences available upon request). 
Electrophoretic Mobility Shift Assays - FHL2, SRF and myocardin factors were in 
vitro translated using the Promega TnT kit. Binding reactions contained 5ul of total TnT 
lysate, a 32P-labeled SM α-actin Intronic CArG probe (20,000 cpm), and 0.25 µg dI·dC in 
 71 
binding buffer (10 mM Tris, pH 7.5, 50 mM NaCl, 100 mM KCl, 1 mM dithiothreitol, 1 mM 
EDTA, 5% glycerol). Reactions were incubated for 30 m before loading on a nondenaturing 
5% polyacrylamide gel. 
Sub-cellular Localization Studies – 10T 1/2 cells were transfected with EGFP-MRTF-
B +/- FHL2. After serum starvation, cells were fixed in 4% paraformaldehyde and EGFP-
MRTF-B localization was then scored into 3 categories: nuclear, cytoplasmic, and diffuse. 
FHL2 knockdown - The following siRNAs were ordered from Invitrogen: Control 
(NTC) - ugguuuacaugucgacuaa, FHL2 - gcaaggacuuguccuacaa. siRNAs were transfected into 
primary rat aortic SMC using dharmafect reagent 1 (Dharmacon) per manufacturer’s 
protocol. FHL2 protein expression in SMC RIPA lysates was measured by Western Blot 
using an anti-FHL2 Ab (Santa Cruz). For promoter-luciferase assays, transfections were 
performed 24 hrs after oligo introduction.  
Detection of ubiquitinated MRTF-A – Myocardin factor expressing or non-expressing 
10T1/2 cells were treated for 12 h with MG132 (20uM), lactacystin (10uM), or DMSO 
vehicle. RIPA lysates were run on an SDS-PAGE gel, transferred to nitrocellulose, and 
probed with anti-flag, anti-tubulin, or anti-MRTF-A Abs. MRTF-A was immunoprecipitated 
from MG132-treated cells using a monoclonal hamster anti-MRTF-A Ab coupled to protein 
G beads (Sigma). Western Blots were performed on immunoprecipitants using the P4G7 
anti-ubiquitin antibody (Covance).  
Determination of MRTF-A half-life – 10T1/2 cells +/- FHL2 were treated with 
cycloheximide (50ug/ml) or vehicle. Endogenous MRTF-A expression was measured by 
Western Blot at 0, 0.5, 3, and 6 h. Similar experiments were done in Cos cells expressing 
flag-MRTF-A and in 10T1/2 cells treated with MG132. 
 72 
RESULTS 
FHL2 interacted with SRF.  To identify novel members of the transcriptional 
complex required for expression of SMC differentiation marker genes, we screened a human 
aortic yeast-two-hybrid library using the N-terminal third of SRF (aa 1-201) as bait. This 
SRF fragment included the inhibitory N-terminal region, nuclear localization signal, and 
MADS box motifs αI (aa 153-179), βI (aa 182-188), and βII (aa 194-198) (see figure 2.1A). 
Three of the fifty interacting clones coded for the LIM-only protein FHL2, and a series of 
secondary yeast screens were performed to eliminate the possibility that the FHL2-Gal4 
activation domain fusion construct activated yeast reporter genes on its own. Using co-
immunoprecipitation assays and GST fusion pull-downs we observed a consistent, but 
relatively weak interaction between FHL2 and SRF (Figs 3.1b and 3.1c). These data confirm 
the observation by Philippar et al that FHL2 interacts with SRF (124).  
FHL2 was strongly expressed in SMC and SMC-containing tissues.  FHL2 
belongs to a subclass of LIM-only proteins that is characterized by four full LIM domains 
and one half LIM domain at the amino termini separated by short linker peptides. To date, six 
members of this family (FHL1-5 and ACT) have been identified that have varying expression 
patterns (26, 41). FHL2 was originally thought to be specifically expressed in the 
myocardium, but examination of mice containing LacZ knocked into the endogenous FHL2 
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locus revealed high expression of FHL2 in the developing vasculature (26). To specifically 
examine FHL2 expression in adult smooth muscle, we used semi-quantitative RT-PCR (Fig 
3.1d). As expected, FHL2 message was highest in the heart, but significant levels were also 
detected in tissues that contain a large SMC component including aorta, bladder, esophagus, 
and stomach. In addition, FHL2 expression was very high in primary rat aortic and A7r5 
SMC, weak in multipotential 10T1/2 cells, and absent in cos-7 cells.  FHL1, which has also 
been shown to be expressed in the developing heart and outflow tract, was expressed in a 
similar pattern (data not shown). 
FHL2 interacted directly with all three myocardin family members.   Based upon 
previous studies demonstrating that the CRP LIM only proteins facilitated the formation of 
an SRF/GATA6 complex and that FHL2’s transcriptional activity, like that of MRTF-A and 
MRTF-B, was regulated by RhoA, we postulated that FHL2 may interact with the myocardin 
factors. As shown in figure 3.2a GST-FHL2 strongly precipitated in vitro translated 
myocardin, MRTF-A, and MRTF-B.  Further mapping studies suggested that full length 
FHL2 was required for strong interactions with myocardin and MRTF-A, while an FHL2 
fragment containing only the N-terminal 2 and 1/2 LIM domains (0-2) could mediate binding 
with MRTF-B (Fig 3.2b). In addition, endogenous MRTF-A co-immunoprecipitated with 
flag-FHL2 expressed in 10T1/2 cells, further suggesting that these proteins interact in vivo 
(Fig 3.2c).  
We also mapped the domains of the myocardin factors that interacted with FHL2. As 
shown in figure 3.2d-f, FHL2 bound most strongly to myocardin, MRTF-A, and MRTF-B 
through an N-terminal fragment that contained the RPEL motifs, the two basic domains, and 
the Q-rich region. Interestingly, FHL2 bound fairly strongly to a myocardin fragment that 
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contained only the RPEL motifs and basic domain 2 (Fig 3.2d) and to an MRTF-B fragment 
that contained only basic domain 1, the Q-rich region, and the SAP domain (Fig 3.2f). Taken 
together, these results suggest that the region near basic domain 1 is probably the most 
important for FHL2 binding. The slight differences in FHL2 binding to the myocardin factors 
were somewhat surprising and suggested that FHL2 may have differential effects on the 
myocardin factors. 
FHL2 enhanced myocardin and MRTF-A transactivation.  To test whether FHL2 
had functional effects on myocardin factor activity we co-expressed FHL2 with each of the 
myocardin factors along with the SMα-actin and SM22 promoters in multipotential 10T1/2 
cells. In these experiments we transfected sub-maximal levels of myocardin, MRTF-A, and 
MRTF-B that activated these promoters by approximately 60, 45 and 10 fold, respectively 
(data not shown). As shown in figure 3.3, co-expression of FHL2 dose-dependently increased 
myocardin’s ability to stimulate SMC-specific promoter activity. In stark contrast, FHL2 
inhibited transactivation by MRTF-B, and slightly stimulated transactivation by MRTF-A but 
only at high concentrations. Because FHL2 expression is the highest in the myocardium, we 
also examined the effects of FHL2 on the cardiac-specific atrial natriuretic factor (ANF) 
promoter. Similar to effects observed with the SMC-specific promoters, FHL2 increased 
transactivation of ANF by myocardin and MRTF-A. We initially hypothesized that FHL2 
increased myocardin and MRTF-A activity by facilitating their interactions with SRF.  
However, expression of FHL2 had no effect on the association of SRF and MRTF-A as 
measured by co-immunoprecipitation of proteins from 10T1/2 lysates (Fig 3.2c) and did not 
increase ternary complex formation between SRF and the myocardin factors in gel shift 
assays (see Fig 3.6, below).  
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 To further explore the role of FHL2 in SMC differentiation marker gene expression, 
we used siRNA to knock down FHL2 expression in primary rat aortic SMC. As shown in 
figure 3.3d, knockdown of FHL2 expression by 90% led to an approximately 50% decrease 
in the activities of the SM α-actin, SM22, and calponin promoters.  
FHL2 protected myocardin and MRTF-A from proteasome-mediated 
degradation.  A recent report demonstrated that FHL2 is a target for the ubiquitin E3 ligase, 
Murf3 (10). Given that other LIM domain containing proteins can inhibit proteasome-
mediated degradation by interacting with E3 ligases or ubiquitin targets (60, 140), we tested 
whether myocardin factor protein levels were regulated by proteasomal degradation and 
whether the positive effects of FHL2 on myocardin factor activity were due to inhibition of 
this pathway. We have recently generated a highly specific monoclonal antibody for MRTF-
A that we first used to determine whether endogenous MRTF-A protein levels were affected 
by FHL2 expression. Even with a transfection efficiency of only 40-50% (measured by 
parallel transfection of GFP), over-expression of FHL2 in 10T1/2 cells led to a significant 
increase (~3-fold) in MRTF-A protein as measured by Western Blot (Fig 3.4a). Importantly, 
over-expression of FHL2 did not affect myocardin factor mRNA levels (Fig 3.4b). Treatment 
of cells with the proteasome inhibitor MG132 resulted in a slightly larger increase in 
endogenous MRTF-A protein in both 10T1/2 cells and primary rat aortic SMC (Fig 3.4c).   
We were also interested in the effects of FHL2 on myocardin and MRTF-B protein 
levels, but because we have had little success in measuring myocardin or MRTF-B protein 
levels with the available antibodies, we co-transfected FHL2 along with flag-tagged versions 
of all three myocardin factors into 10T1/2 cells.  As shown in figure 3.4d, over-expression of 
FHL2 led to increased levels of exogenously expressed myocardin (compare lanes 1 and 2) 
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and MRTF-A (lanes 3 and 4), but had no effect on levels of MRTF-B (lanes 5 and 6). 
MG132 treatment led to more dramatic increase in myocardin and MRTF-A protein, and 
slightly increased MRTF-B levels (Fig. 3.4e, compare lanes 1 and 2). Interestingly, FHL2 
expression had little if any effect on myocardin and MRTF-A levels in MG132-treated cells 
(compare lanes 2 and 4). We observed very similar changes in myocardin factor protein 
levels upon treatment of cells with lactacystin, a more specific inhibitor of the proteasome 
(Fig. 3.4f). 
Interestingly, FHL2’s ability to protect the myocardin factors from degradation 
correlated fairly well with myocardin factor nuclear localization. For example, myocardin 
which is constitutively nuclear, exhibited relatively lower expression levels under control 
conditions and was protected from degradation by FHL2. In contrast, MRTF-B, which is 
frequently cytoplasmic, was expressed at much higher levels but was not up-regulated by 
FHL2 expression.  To test this more rigorously, we compared the effects of MG132 and 
FHL2 on ΔN MRTF-B, which lacks the N-terminal RPEL motifs that are required for 
localization of MRTF-B to the cytoplasm. ΔN MRTF-B levels were much lower than full-
length MRTF-B levels under control conditions, and unlike full-length MRTF-B,  ΔN 
MRTF-B protein levels were up-regulated by FHL2 co-expression and were strongly up-
regulated by MG132 treatment (Fig 3.4e; bottom panel).  
To directly measure the effects of FHL2 on MRTF-A protein stability we treated cells 
with the protein synthesis inhibitor, cycloheximide and measured MRTF-A protein by 
Western blot at 0.5, 3, and 6 h. As shown in figure 3.5, the half-life of over-expressed or 
endogenous MRTF-A was approximately 3 h and was significantly extended by the 
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expression of FHL2 (Figs 3.5a and 3.5b) or by proteasome inhibition (Fig 3.5c). Note that the 
protein half-life of FHL2 was substantially shorter (~1.5 h).  
To determine whether the myocardin factors were targeted to the proteasome by 
ubiquitination, we immunoprecipitated MRTF-A from MG132-treated and control SMC and 
probed immunoprecipitates with an anti-ubiquitin antibody. As shown in figure 3.5d, 
ubiquitin immunoreactivity was only detected in MRTF-A (not control IgG) 
immunoprecipitants, and treatment of SMC with MG132 resulted in a substantial increase in 
this signal. 
FHL2 did not increase myocardin factor association with SRF and may 
negatively regulate SRF-CArG binding.  Philippar et al reported that FHL2 expression 
inhibited RhoA-dependent increases in SM22 and SM α-actin promoter activity in 293T cells 
and based upon gel shift analyses suggested that this effect was due to competitive inhibition 
of myocardin factor binding to SRF (20). We observed similar effects of FHL2 on RhoA-
dependent stimulation of SMC-specific transcription in our 10T1/2 model (data not shown) 
and also demonstrated that FHL2 had negative effects on MRTF-B transactivation (Fig 3.3). 
However, our demonstration that FHL2 interacts directly with the myocardin factors and has 
differential effects on myocardin factor transactivation potentially complicates this model.  
Based upon our observation that FHL2 binds slightly differently to each myocardin 
factor we used gel shift assays to test whether FHL2 had differential effects on myocardin 
factor binding to the SRF-CArG complex.  Because the N-terminal RPEL domains of 
MRTF-A and MRTF-B inhibit their incorporation into the SRF-containing ternary complex, 
full-length and amino-terminally truncated variants (ΔN) of the MRTFs were used in these 
assays. Results shown in figure 3.6a demonstrate that only myocardin and the ΔN forms of 
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the MRTFs formed ternary complexes with SRF at the SM a-actin CArG B element. 
Addition of in vitro translated FHL2 to the binding reaction slightly decreased the intensity 
of all SRF containing complexes including those that did not contain a myocardin factor. 
This observation was particularly evident in the binding reactions that contained SRF only 
(far right). Taken together, although FHL2 did slightly decrease the levels of ternary 
complex, this was likely due to an overall reduction in SRF-CArG binding. 
FHL2 modestly inhibited MRTF nuclear translocation.  FHL2, like the MRTFs, 
has been shown to translocate from the cytoplasm to the nucleus in response to external 
stimuli that activate RhoA (110). Given that the effects of RhoA are strongly dependent upon 
nuclear translocation of the MRTFs, we hypothesized that the inhibitory effects of FHL2 
could also be due to inhibition of MRTF-B nuclear translocation.  To test this, we co-
expressed flag-FHL2 along with EGFP-MRTF-B fusion proteins. MRTF-B localization 
under serum-free conditions was scored as nuclear, cytoplasmic, or diffuse (nuclear + 
cytoplasmic). As shown in figure 3.6b, expression of FHL2 slightly increased the percentage 
of cells exhibiting strictly cytoplasmic localization and decreased the percentage of cells 
exhibiting diffuse localization. 
DISCUSSION 
FHL2 has been shown to interact with a large number of transcription factors in a 
number of different model systems and has been shown to have both positive and negative 
effects on gene expression (see (67) for review).  The goal of the present study was to further 
characterize the effects of FHL2 on SRF-dependent transcription. While our results confirm a 
previous report that FHL2 interacts directly with SRF, they also suggest that FHL2’s role in 
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the regulation of SRF-dependent transcription is complicated by additional interactions with 
the myocardin family of SRF co-factors.  We demonstrate for the first time that expression of 
FHL2 stimulates myocardin-dependent transactivation of cardiac and SMC-specific promoter 
activity and that these effects are most likely due to protection of myocardin and MRTF-A 
from proteasomal degradation. Thus, based upon the known expression pattern of FHL2 
during development, we propose that FHL2 promotes cardiac and SMC differentiation by 
preserving myocardin factor protein levels. In addition, since the FHL2 and SRF promoters 
are both regulated by SRF (124) (and probably the myocardin factors), FHL2 could be a key 
component of a feed-forward mechanism that maintains high levels of cardiac- and/or SMC-
specific gene expression. 
To our knowledge, these studies are the first to demonstrate that the myocardin 
factors are regulated by the proteasome and may provide a novel mechanism for the control 
of cardiac and SMC-specific transcription. Our finding that endogenous MRTF-A is 
ubiquitinated suggests that the myocardin factors may be direct targets for the proteasome, 
but it remains possible that myocardin factor stability is also regulated by another mechanism 
that is proteasome-sensitive. In addition, although the effects of FHL2 on MRTF-A protein 
half-life strongly suggest that FHL2 stabilizes myocardin factor protein, we cannot 
completely rule out an additional effect of FHL2 on the translation of myocardin factor 
message.  
Previous studies have shown that FHL2's effects on gene expression are affected by a 
number of parameters including cellular localization and interactions with a variety of 
general and cell-type-specific transcription factors. The positive and negative transcriptional 
effects of FHL2 observed in this study likely reflect a combination of these differences. For 
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example, although FHL2 may attenuate cardiac and SMC-specific promoter activity by 
inhibiting ternary complex formation or MRTF-B nuclear translocation, these effects may be 
counteracted by increased myocardin and MRTF-A protein levels. The failure of FHL2 to 
protect MRTF-B from degradation may help explain the negative effects of FHL2 on MRTF-
B transactivation.  It is also possible that the negative effects of FHL2 may be due to 
sequestration of the myocardin factors or SRF into inactive complexes. 
It is currently unclear why FHL2 does not affect MRTF-B stability. Our results, 
especially the comparison between full-length and ΔN MRTF-B, demonstrated that 
myocardin factor protein levels and the ability of FHL2 to protect individual myocardin 
factors from degradation were affected by nuclear localization. These results suggest the 
interesting possibility that myocardin factor ubiquitination occurs mainly in the nucleus. It is 
also possible that small differences in FHL2 binding to each myocardin factor could affect 
interactions with the ubiquitination or proteasome machinery.   
Other LIM-domain containing proteins have also been shown to inhibit 
ubiquitination. Sangadala et al demonstrated that LIM-mineralization protein-1 stimulated 
osteoblast differentiation in mesenchymal cells by an inhibitory interaction with the E3 
ligase, Smurf1, and that this interaction prevented SMAD degradation (140).  In addition, 
Hiratani et al demonstrated that the Xenopus LIM homeodomain protein, Xlim-1, prevented 
the degradation of its binding partner, Ldb1, by the E3 ligase XRnf12 (60). Importantly, 
during the preparation of this manuscript, Fielitz et al identified FHL2 as a substrate for the 
E3 ligase Murf3 (40), and a very important future goal is to determine whether the myocardin 
factors are potential targets of the MuRF proteins. Although we did not detect FHL2 in 
complex with the SRF myocardin factor complex by gel shift, flag-FHL2 was detected at the 
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CArG-containing regions of the SM α-actin and SM22 promoters in vivo (124). If FHL2 and 
the myocardin factors are targets of the same E3 ligase, FHL2 could shield the myocardin 
factors from degradation by competitively interfering with myocardin factor ubiquitination. 
This would lead to stabilization of an important component of the SMC-specific transcription 
initiation complex and increased SMC differentiation marker gene expression. 
Deletion of FHL2 in the mouse did not result in an overt cardiac phenotype (25) , but 
it is unknown whether other FHL family members (most likely FHL1) can compensate for 
loss of FHL2 in this model. Importantly, FHL2 -/- mice were more susceptible to 
isoproterenol-induced the lack cardiac hypertrophy (70) suggesting that FHL2 does have a 
specific cardiac function. Although the effects of FHL2 deficiency on SMC function have not 
been directly examined, a recent study by Wixler et al indicates that FHL2 regulates SMC 
differentiation marker gene expression in vivo (184).  These authors observed that FHL2 was 
activated in skin myofibroblasts following wounding and that FHL2 expression correlated 
with the activation of SM α-actin and SM22 expression that is known to occur in this model 
(59). Furthermore, they demonstrated that FHL2 -/- mice exhibited reduced SM α-actin 
expression and healing following wounding and that re-expression of FHL2 in FHL2 -/- 
MEFs and mesenchymal stem cells up-regulated SM α-actin promoter activity. These results 
support a closer examination of the role of FHL2 in the modulation of SMC phenotype 
following vessel injury. 
In summary, FHL2 has multiple effects on SRF- and myocardin factor-dependent 
transcription. Our data suggest that that FHL2 protects myocardin and MRTF-A from 
proteasome mediated degradation, providing a novel mechanism for the control of myocardin 
factor activity. It will be very important to further characterize this regulatory mechanism in 
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cardiac and SMC and to test whether FHL2 (and perhaps other FHL family members) has 
similar effects on other transcription factors. 
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ABSTRACT 
Members of the myocardin family of SRF cofactors play a central role in cardiac and 
smooth muscle cell-specific gene expression, yet little is known about their regulation. Here, 
we extend recent findings that these transcription factors are regulated by proteasomal 
degradation, and report that the muscle-specific ring finger protein MuRF3 likely acts as an 
E3 ubiquitin ligase for the myocardin factors. Over-expression of MuRF3 inhibited SM α-
actin promoter activity in luciferase assays, and significantly reduced the capacity of 
myocardin factors for transactivating the SM α-actin or SM22 promoters. MuRF3 physically 
interacted with the myocardin factors and down-regulated their expression in culture. 
Examination of hearts and multiple smooth muscle rich organs from wild-type and MuRF3-/- 
mice revealed increased abundance of MRTF-A protein in the absence of MuRF3. 
Preliminary in vivo ubiquitination assays demonstrated that over-expression of MuRF3 
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increased the ubiquitinated fraction of MRTF-A, suggesting that the myocardin factors may 
be substrates for its ubiquitin ligase activity. 
INTRODUCTION 
Vascular smooth muscle cells (SMC) play a critical role in vasculogenesis and 
angiogenesis, and provide mature vessels with the capacity for contraction necessary for 
proper maintenance of blood pressure and distribution throughout the organism. SMC arise 
from multiple origins within the embryo including the proepicardial organ, the cardiac neural 
crest, local mesoderm, and potentially from circulating stem cells as well (see (122) for 
review). Unlike other muscle cell types, SMC do not undergo terminal differentiation, but 
retain a unique phenotypic plasticity that facilitates their involvement in vascular remodeling 
and injury repair. In response to aberrant signaling, this phenotypic plasticity also facilitates 
the involvement of SMC in the pathogenesis of multiple prominent cardiovascular disease 
states including hypertension, atherosclerosis, and post-angioplasty restenosis. A greater 
understanding of the mechanisms governing SMC differentiation will undoubtedly increase 
our knowledge of vascular development and our ability to treat cardiovascular disease. The 
elucidation of these mechanisms, however, has been complicated by many factors including 
the varied origins of SMC and their lifelong capacity for phenotypic modulation. 
It is well accepted that the expression of nearly all SMC differentiation marker genes, 
including SM MHC, SM α-actin, and SM22, is driven by the binding of the transcription 
factor serum response factor (SRF) to a conserved region within the promoters of these genes 
known as CArG (C(A/T)6G) boxes. SRF however, is ubiquitously expressed and is also 
involved in the CArG-dependent regulation of multiple other non-SMC genes including the 
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early response genes c-fos and egr-1, as well as many skeletal and cardiac muscle-specific 
genes. It follows therefore that other factors in addition to SRF are necessary for specifying 
SMC fate. An important advance in our understanding of the mechanisms governing SMC 
differentiation came with the discovery of the myocardin family of transcription factors (53, 
175, 176) that includes myocardin and the myocardin-related transcription factors A and B 
(MRTF-A and MRTF-B). The myocardin factors have been shown to interact directly with 
SRF and to potently up-regulate SRF/CArG-dependent expression SMC differentiation 
marker genes. While the myocardin factors have been shown to be important in promoting 
the expression of SMC differentiation marker genes over growth genes, they have also been 
shown to up-regulate expression of cardiomyocyte differentiation marker genes in a similar 
manner. Thus, it remains an important goal to identify pathways that determine cardiac 
versus SMC fate, and to determine how the myocardin factors may be involved in these 
pathways.  
Recent experiments performed in our laboratory have demonstrated that degradation 
of myocardin and MRTF-A could be inhibited via novel interactions with the LIM-only 
protein four and a half LIM domains 2 (FHL2) (manuscript under review). Addition of FHL2 
increased myocardin- and MRTF-A-dependent transactivation of the SM α-actin and SM22 
promoters. FHL2 did not affect myocardin factor mRNA levels, but significantly increased 
the protein half-lives of both myocardin and MRTF-A. Further experiments strongly 
implicated the ubiquitin-proteasome system (UPS) as a mediator of myocardin factor 
stability, and demonstrated that this may be an important mode of regulating their activities. 
Treatment of cells with the proteasome inhibitors MG132 and lactacystin resulted in 
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increased protein stability of all three myocardin family members, and ubiquitination of 
MRTF-A was established by co-immunoprecipitation in SMC.  
The importance of the UPS in cardiovascular development and disease is still 
emerging. The UPS has long been recognized as a regulator of multiple cellular processes 
including cell cycle progression and control of transcription (86, 113). More recent reports 
have directly implicated the UPS as a major player in the progression of cardiac-specific 
disease, and as an important regulator of normal cardiac function (see (183) for review). 
Importantly, recent studies have also linked the UPS to multiple pathways in SMC, including 
RhoA signaling and SRF-dependent gene expression (133, 139).  
Protein ubiquitination occurs by a three-step process, each relying on a specific class 
of enzyme (E1-E3). Substrate specificity is conferred during the final step of this process, in 
which an E3 ubiquitin ligase transfers the ubiquitin molecule directly to the substrate. Mono-
ubiquitination of substrates has been demonstrated to result in various effects, including 
alterations in protein activity and localization, while poly-ubiquitination most often leads to 
degradation via the 26S proteasome (see (113) for review). To understand the signaling 
mechanisms that regulate proteasomal degradation of the myocardin factors, it will be 
important to identify the E3 ligases responsible for their ubiquitination. 
Interestingly, Olson and colleagues have recently reported that FHL2 interacts with 
the E3 ubiquitin ligase muscle-specific RING finger 3 (MuRF3), and presented compelling 
data suggesting that FHL2 is a target of MuRF3-mediated proteasomal degradation (40). 
MuRF3 belongs to a subset of RING-finger E3 ubiquitin ligases that also includes MuRF1-
and MuRF-2, all of which are believed to be expressed exclusively in striated muscle (17, 
153). Accordingly, nearly all studies of the MuRF family proteins to date have focused on 
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their role in skeletal and cardiac muscle. MuRF1 has been shown to catalyze the 
ubiquitination and degradation of troponin I in cardiomyocytes, and to play a role in skeletal 
muscle atrophy and cardiac hypertrophy (8, 69, 182).  MuRF2 also interacts with the 
sarcomeric apparatus, and has additionally been implicated as a mechanical stress-induced 
modulator of SRF activity in cardiomyocytes (74). MuRF3 has been shown to play an 
important role in microtubule assembly and is required for skeletal muscle differentiation and 
maintenance of ventricular integrity following myocardial infarction (40, 47, 153). Thus far, 
none of the MuRF family proteins have been shown to play a role in the modulation of SMC 
gene expression. 
In light of our earlier findings that FHL2 protected myocardin and MRTF-A from 
proteasomal degradation, and the recent report indicating FHL2 is a binding partner of the E3 
ubiquitin ligase MuRF3, we hypothesized that MuRF3 may also mediate the degradation of 
myocardin factors. Our results indicate that MuRF3 inhibits myocardin factor-mediated 
transactivation of SMC gene promoters and down-regulates myocardin factor expression in 
vitro and in vivo. Importantly, MuRF3 also physically interacted with the myocardin factors, 
and may act as an E3 ubiquitin ligase that facilitates their ubiquitination.  
MATERIALS AND METHODS 
 Plasmids and Reagents  – Flag-pcDNA3-Myocardin, MRTF-A, and MRTF-B, as 
well as the SMα-actin, SM22, and CRE luciferase promoter constructs have been previously 
described (58). Myc-pcDNA3.1-MuRF3 and rabbit anti-MuRF3 Ab were generous gifts of 
Monte Willis (University of North Carolina). Flag-ubiquitin was a generous gift of Liliana 
Ponguta and Elizabeth Wilson (University of North Carolina). Monoclonal anti-MRTF-A Ab 
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was generated by immunization of hamsters with MRTF-A peptide. All other Abs were 
commercially obtained including goat anti-MRTF-B (Santa Cruz) rabbit anti-FAK (Upstate), 
mouse anti-α-tubulin (Sigma), and mouse anti-ubiquitin (Covance). 
 Cell Culture, Transient Transfections, and Reporter Assays – 10T1/2 cultures and the 
SMC-specific promoter assays used have been previously described (88).  In brief, cells were 
maintained in 10% serum media and transfected 24 h after plating at 70-80% confluency 
using LT-1 transfection reagent (Mirus) per protocol. Luciferase activity measurements were 
made 24 h post transfection. Luciferase activity was measured in relative light units (RLUs) 
and expressed as fold activity over empty vector. For harvesting of protein, cells were 
transfected in 10cm dishes using LT-1 reagent as above and lysed in RIPA + 0.5% triton.  
 GST fusion pull-downs and co-immunoprecipitations - GST pull-down assays and co-
immunoprecipitations were performed as previously described (157). In brief, GST fusion 
proteins were purified from bacterial lysates using glutathione sepharose (Amersham 
Biosciences). Whole cell lysates were prepared from rat hearts as follows: organs were 
perfused with phosphate-buffered saline, excised from animals, homogenized, and lysed in 
RIPA+1% triton. For pull-downs, GST fusions were used to precipitate MuRF family 
proteins, and for co-immunoprecipitations endogenous MRTF-A was precipitated using 
hamster anti-MRTF-A Ab. Interacting complexes were pelleted by centrifugation and 
washed 3X in  RIPA buffer and 1X in cold Tris-buffered saline.  
 Semi-quantitative PCR - RNA was prepared from cell and tissue lysates using Trizol 
Reagent (Invitrogen) and was quantified by optical density assay. cDNA was generated from 
1ug of RNA using in the iScript cDNA synthesis kit (Biorad). Exon spanning primers were 
used to amplify MuRF3 and GAPDH (sequences available upon request).  
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 In vivo ubiquitination assays –10T1/2 cells were transfected with myc-MuRF3 and 
flag-ubiquitin or flag empty vector and treated for 12 h with MG132 (10uM) (Sigma). Cells 
were lysed in RIPA buffer and immunoprecipitations were performed using M2 anti-flag 
(Sigma) or hamster anti-MRTF-A Abs coupled to protein G beads (Sigma). Precipitants were 
run on an SDS-PAGE gel, transferred to nitrocellulose, and probed with P4G7 anti-ubiquitin 
(Covance) or monoclonal anti-MRTF-A Abs.  
RESULTS 
MuRF3 was detected in heart and aorta and inhibited SM α-actin promoter 
activity. MuRF3 expression is thought to be limited to striated muscle, yet Spencer et al have 
reported that extended exposures of Northern analyses revealed low level MuRF3 mRNA 
expression in lung (an organ with a large SMC component), and no reports to date have 
specifically examined the expression of MuRF3 in smooth muscle (153).  To further evaluate 
this question, we performed semi-quantitative RT-PCRs on RNA extracted from mouse 
hearts, primary cultures of rat aortic SMC, and multiple immortalized cell lines. As shown in 
figure 4.1A, MuRF3 mRNA expression was greatest in heart, as previously reported, but was 
also detectable at very low levels in primary cultures of SMC and in Cos-7 cells.  MuRF3 
mRNA was not detected in immortalized A7R5 SMC, or in 10T1/2 cells, which have been 
shown to differentiate into SMC upon treatment with TGF-β. We also examined MuRF3 
protein levels in lysates derived from rat heart and aorta, and observed similar levels of 
MuRF3 protein in both organs (Fig 4.1B). The striking difference between MuRF3 mRNA 
levels in primary cultures of aortic SMC and MuRF3 protein levels in aortic lysate was 
surprising, and may reflect cell-type specific differences in post-transcriptional regulation of 
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MuRF3 message or rapid down-regulation of MuRF3 gene expression upon culture of SMC. 
At this time, we also cannot rule out nonspecific interaction of MuRF3 antibody with MuRF1 
or MuRF2, as this antibody was generated before the existence of these two proteins was 
reported (17, 153). 
MuRF3 inhibited transactivation of SMC marker genes by myocardin factors. 
To determine whether MuRF3 has any effect on SMC differentiation marker gene promoter 
activity, we first performed transcriptional reporter assays in which the SM α-actin or 
minimal CRE promoter was used to drive the luciferase reporter gene in the SMC precursor 
10T1/2 cell line. Interestingly, co-transfection of increasing concentrations of MuRF3 with 
the SM α-actin promoter construct resulted in slightly decreased luciferase activity, while co-
transfection with the CRE promoter construct resulted in no effect (Fig 4.1C,D).  
We further explored the role of MuRF3 in SMC-specific transcription by testing its 
effects on myocardin factor transactivation. Co-transfection of increasing concentrations of 
MuRF3 with myocardin or MRTF-B decreased each transcription factor’s ability to trans-
activate either the SM α-actin or SM22 promoter in a dose-dependent manner (Fig 4.2A-B). 
A similar trend resulted upon co-transfection of increasing concentrations of MuRF3 with 
MRTF-A, although a statistically significant level of MRTF-A inhibition was not reached in 
these experiments (Fig 4.2A-B). As was observed before, addition of MuRF3 had no effect 
on CRE promoter activity, regardless of myocardin factor co-transfection (Fig4.2C). 
MuRF3 down-regulated myocardin factor protein expression in vitro and in vivo. 
Because we have previously reported that the myocardin factors are regulated via 
proteasomal degradation, and MuRF3 is known to act as an E3 ubiquitin ligase, we tested 
whether MuRF3 expression had any effect on myocardin factor protein expression levels. We 
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did this first by co-transfecting each of the myocardin factors with either MuRF3 or empty 
vector, and measuring the expression of exogenous myocardin factor protein by Western 
analysis. Addition of MuRF3 strongly inhibited myocardin and MRTF-B expression, and led 
to the breakdown of exogenously expressed MRTF-A (Fig 4.3B). To further explore the 
effect of MuRF3 expression on MRTF-A protein expression, we transfected cells with either 
MuRF3 or empty vector, and measured the effects of MuRF3 expression on endogenous 
MRTF-A. Lack of suitable antibodies precluded examination of endogenous myocardin and 
MRTF-B protein. As shown in figure 4.3A, transfection of MuRF3 resulted in reduced 
protein levels of endogenous MRTF-A by approximately 50%. While this effect is less 
striking than that seen upon co-transfection of MuRF3 with myocardin and MRTF-B, these 
data may underestimate the potency of MRTF-A protein inhibition by MuRF3, as our 
transfection efficiency in this cell type is only 40-50%.  
We next examined myocardin factor expression levels in the hearts and multiple 
smooth muscle-containing organs of wild-type and MuRF3 knockout mice. The mice used in 
these studies were obtained from the Willis laboratory, and genetic deletion of MuRF3 was 
accomplished using the same knock-in approach as has been previously published for 
MuRF1(8, 182). Deletion of MuRF3 in the mice tested by our laboratory was confirmed by 
PCR (data not shown). Due to lack of a suitable antibody against myocardin, our examination 
of myocardin factor protein levels in these tissues was limited to MRTF-A and MRTF-B. As 
predicted based on the over-expression studies described above, MRTF-A protein was up-
regulated in the hearts, aorta, lung, and bladder of MuRF3-/- mice (Fig 4.3C). No differences 
in MRTF-B protein expression were detected between wild-type and MuRF3-/- mice using a 
sub-optimal commercially available antibody to MRTF-B (data not shown).  
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 MuRF3 physically interacted with the myocardin factors. Poly-ubiquitination of 
proteins is most often initiated by E3 ligases, which interact with both the E2 ubiquitin 
conjugating enzyme, and with the substrate protein to facilitate transfer of the ubiquitin 
molecule (172). To begin to explore the possibility that MuRF3 may act as an E3 ligase for 
the myocardin factors, we conducted experiments to detect an interaction between the 
proteins. Immunoprecipitation of endogenous MRTF-A from rat heart lysate resulted in co-
immunoprecipitation of endogenous MuRF3, indicating that the two proteins do interact in 
vivo (Fig 4.4A). We next used GST fusion pull-down experiments to further substantiate an 
interaction between MuRF3 and MRTF-A and to investigate possible interactions between 
other MuRF family members and MRTF-A or MRTF-B. As shown in figure 4.4B, MRTF-A 
and MRTF-B were precipitated from rat heart lysate using GST-fusions of both MuRF1 and 
MuRF3, but not MuRF2. Lack of a suitable antibody against myocardin again limited our 
examination to MRTF-A and MRTF-B in these experiments.  
MuRF3 may act as an E3 ubiquitin ligase for the myocardin factors. The data 
presented thus far have demonstrated that MuRF3 interacts with at least MRTF-A and 
MRTF-B (myocardin was not examined) and down-regulates the protein levels of all three 
myocardin factors (Figs 4.3-4.4). To further assess the ability of MuRF3 to act as an E3 
ligase for myocardin factors, we performed in vivo ubiquitination assays of MRTF-A in the 
presence and absence of over-expressed MuRF3. We recently used a similar assay to 
demonstrate that MRTF-A is ubiquitinated in vivo (manuscript under review). These 
experiments have been only marginally successful (data not shown). We have also attempted 
to demonstrate MuRF3-mediated ubiquitination of the myocardin factors using in vitro 
ubiquitination assays, but have thus far been unsuccessful (data not shown).  
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DISCUSSION 
The goal of the present study was to explore a potential role for MuRF3 in the 
regulation of myocardin factor stability and SMC-specific transcription. The data presented 
here demonstrate for the first time that MuRF3 inhibits transactivation of the SM α-actin and 
SM22 gene promoters. We also show that MuRF3 down-regulates myocardin factor protein 
levels, physically interacts with MRTF-A and MRTF-B, and may act as an E3 ubiquitin 
ligase for this very important family of SRF co-factors. While MuRF3 was shown to down-
regulate exogenous myocardin protein levels as well, an interaction between MuRF3 and 
endogenous myocardin was not investigated due to lack of suitable antibody. A present goal 
is to evaluate this possibility using ectopic expression studies. To our knowledge, the 
myocardin factors have not previously been identified as potential substrates for any other E3 
ubiquitin ligase. These findings provide information critical to our understanding of the roles 
played by MuRF family proteins and the UPS in regulating SRF-dependent SMC-specific 
transcription. 
Thus far, we have been unable to directly demonstrate ubiquitination of myocardin 
factors by MuRF3. We have attempted to do this using in vitro ubiquitination assays. 
Potential reasons for our lack of success in these experiments, as well as alternative future 
approaches, are discussed below.  
In vitro ubiquitination assays require the addition of purified substrate protein. We 
have attempted to isolate myocardin factor protein from both yeast and insect cell systems. 
GST fusions of the myocardin factors were unstable in yeast, and insect cells infected with 
myocardin factor-encoding baculovirus grew at very low rates compared to uninfected cells. 
Ultimately, our attempts at isolation of full-length myocardin factor protein from cells have 
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been unsuccessful. This may be partially explained by the short half-lives of myocardin 
factors observed in mammalian cells (Fig 3.5). Rapid turnover of these proteins in yeast 
and/or insect cells might explain the degradation we have observed. In addition, Tang et al 
have recently shown that myocardin inhibits cellular proliferation by inhibiting NF-κB 
mediated cell-cycle progression (161). These findings may explain the lack of cellular 
growth observed in myocardin factor encoding baculovirus-infected insect cells.   
We have had past success in generating recombinant myocardin factor protein using 
an in vitro transcription/translation coupled system (Promega). The amount of protein 
produced in this system is insufficient for visualizing the relatively small percentage of 
protein that undergoes ubiquitination in these assays by Western analysis, but radiolabeling 
of proteins with 35S should overcome this problem. It may also be important to perform these 
experiments in the presence and absence of whole cell extracts (WCE) to determine if there 
are additional accessory factors (such as SRF, discussed below) that are required for the 
ubiquitination of MRTFs by MuRF3. WCE should be prepared from cells that do not express 
MuRF3, so that the presence of MuRF3 can be controlled for. 
MuRF3 was originally identified in a yeast-2-hybrid screen for binding partners of 
SRF in adult mouse heart, yet subsequent attempts to demonstrate this interaction or co-
localization of the two proteins were unsuccessful (153). The myocardin factors are known to 
interact with SRF and are expressed in the myocardium. Under certain conditions, MuRF3 
may form complexes with SRF-bound myocardin factors, providing a possible explanation 
for detection of MuRF3 in the above screen.  
The idea that MuRF3 may bind to myocardin factors in complex with SRF is further 
supported by a recent examination of the proteasome’s role in regulating transcription in vivo 
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(106). In this study Molinari et al demonstrated that transcriptional activator protein levels 
did not correlate with mRNA levels, but were tightly regulated post-translationally by the 
ubiquitin-proteasome system. These authors further showed that protein turnover rate is 
directly correlated with potency of transcriptional activation domain and that mutations to 
DNA binding domains of transcriptional activators protected them from degradation, 
indicating that the proteasomal system is capable of both sensing and regulating 
transcriptional activity. The myocardin factors do not bind DNA directly, but exert 
transcriptional activation via interactions with DNA-bound SRF. It follows therefore, that 
proteasomal regulation of myocardin factor function in transcription would be dependent on 
SRF binding, and that interactions with the E3 ligase MuRF3 might be initiated while 
myocardin factors are still in complex with SRF (see figure 4.6 for model).  
This model of proteasomal regulation of myocardin factor-dependent transcription 
also fits nicely with other recent findings.  We have previously demonstrated that 
proteasome-mediated degradation of myocardin factors correlates well with nuclear 
localization, as does protection from degradation by FHL2 (see figure 3.4E in previous 
chapter). It is likely that myocardin factor degradation is associated with nuclear localization 
because ubiquitination of these factors occurs after initiation of transcriptional complex 
incorporation. An important future aim will be to test this experimentally.  
While the mechanism by which FHL2 protects the myocardin factors from 
degradation is still unclear, the data presented here provide the basis for plausible 
hypotheses. FHL2 interacts directly with SRF and the myocardin factors (see figures 3.1 and 
3.2 in previous chapter), and it is possible that FHL2-bound myocardin is resistant to 
ubiquitination by MuRF3. Alternatively, FHL2 also interacts with and is degraded by 
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MuRF3 (40), and may prevent the ubiquitination of myocardin factors by competitive 
inhibition. 
It remains possible however, that the myocardin factors are not ubiquitinated by 
MuRF3, and that MuRF3 exerts its effects on their protein expression by some as yet 
undefined mechanism. For instance, we have shown that FHL2 extends the half-life of 
myocardin and MRTF-A (Fig 3.4), and FHL2 is also a substrate for MuRF3 mediated 
ubiquitination (40). MuRF3 could therefore lead to down-regulation of myocardin and 
MRTF-A protein by promoting the degradation of FHL2. This model would not explain 
MuRF3-mediated inhibition of MTRF-B, as FHL2 did not promote its stability, but 
degradation of a similar protein by MuRF3 would have potentially similar effects. A logical 
first step in evaluating these possibilities will be to obtain more conclusive data regarding the 
ubiquitination of myocardin factors by MuRF3 using modified in vitro ubiquitination assays 
as described above. 
Findings presented here demonstrate that MuRF3 regulates myocardin factor protein 
levels, and is capable of significant effects on SMC-specific transcription. This study is the 
first to demonstrate that MuRF3 protein is present in the vasculature, and the function of 
MuRF3 in vessels has not yet been examined. However, it is known that MuRF3-/- mice do 
not exhibit defective cardiac or SMC differentiation. Olson and colleagues have recently 
reported that while the hearts of MuRF3 null mice appear to develop properly, MuRF3 is 
important for protection of cardiomyocytes following myocardial infarction, and that mice 
lacking MuRF3 exhibit abnormal sarcomeric structure due at least in part to increased 
abundance of FHL2 and γ-filamin (40). It will be interesting to determine whether levels of 
myocardin factors are similarly dysregulated in this injury model, and whether MuRF3-/- 
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mice also exhibit altered function in SMC under pathologic stress. This question should be 
addressed using established models of induced hypertension and restenosis. 
Additionally, we have shown that MuRF1 also interacts with the myocardin factors 
MRTF-A and MRTF-B in heart. It will be important to determine whether MuRF1 or 
MuRF2 play similar roles to MuRF3 in the regulation of myocardin factor degradation. It is 
very possible that loss of MuRF3 in mouse is compensated for by redundancy in function 
with other MuRF family proteins, and a greater understanding of the in vivo importance of 
these factors may require examination of mice in which these genes have been 
combinatorially deleted. Olson and colleagues have very recently reported that tandem 
deletion of MuRF1 and MuRF3 predisposes mice to striated muscle myopathies caused by 
increased accumulation of myosin heavy chain. This study reported no effects on myocardin 
factor stability or SMC function (39). To our knowledge, no other combinatorial deletions of 
the MuRF family proteins have been reported. 
The data presented here further our knowledge of a recently described regulatory 
pathway in SMC-specific gene expression. While these studies are preliminary, they suggest 
the UPS may tightly regulate myocardin factor protein turnover via MuRF3. They also 
provide a basis for further exploration of UPS-mediated controls of SMC-specific 
transcription.  
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PERSPECTIVES AND FUTURE DIRECTIONS 
DISTINCT ROLES FOR MYOCARDIN FACTORS IN VASCULAR DEVELOPMENT 
The studies included here have focused largely on the regulation and activities of the 
very important myocardin family transcription factors in tissue culture and in vitro model 
systems. Since the time that this dissertation research was begun, several studies have 
increased our understanding of individual myocardin factor function in vivo, and are 
important to a discussion of future studies in the field. As was described in the Background 
and Significance chapter of this dissertation, genetic deletion of myocardin results in 
embryonic lethality due to severe vascular defects caused by defective SMC differentiation, 
indicating that myocardin is requisite for smooth muscle development (82).  Until recently, 
the in vivo role of the MRTFs was less clear. 
Multiple laboratories have now shown that genetic deletion of MRTF-B in the mouse 
also leads to embryonic lethality caused by severe cardiovascular defects, including 
incomplete SMC differentiation. Mice homozygous for a loss of MRTF-B display defective 
cardiac outflow tract development. This region of the vasculature arises from progenitor cells 
within the cardiac neural crest, a region where MRTF-B is highly expressed. Loss of MRTF-
B is accompanied by a lack of SMC differentiation marker gene expression in cardiac neural 
crest-derived cells, and specific restoration of MRTF-B expression in these cells is sufficient 
to rescue the MRTF-B -/- phenotype (78, 117). In a similar study performed by Wei et al, 
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these authors demonstrated that MRTF-B -/- mice also exhibit defective SMC gene 
expression in the liver sinusoids, vitilline veins, and yolk sac, extending our understanding of 
the in vivo role of MRTF-B (180).  
The role of MRTF-A in regulating SMC differentiation in vivo is still somewhat 
unclear. It has been reported that MRTF-A knock out mice are viable, indicating that it is not 
required for SMC specification as is myocardin (177). Yet, two recent studies have shown 
that female mice deficient for MRTF-A are unable to nurse their offspring due to defective 
myoepithelial cell differentiation. Myoepithelial cells function similarly to SMC and provide 
the mammary gland with a contractile capacity necessary for milk ejection. MRTF-A -/- mice 
lack SRF-dependent contractile gene expression in these cells (81, 156). Whether other 
myocardin family members compensate for the loss of MRTF-A in SMC will not be known 
until mice are generated with multiple deletions of this family. It is also unclear whether 
MRTF-A is required for other aspects of SMC function such as changes in gene expression 
that are known to occur due to environmental stresses or whether MRTF-A is responsible for 
SMC marker gene expression in other non SMC-types like that observed in myofibroblasts 
during wound healing (31). 
Deletion of each of the myocardin factors yields a distinct phenotype, indicating that 
each plays a unique role in cardiovascular development. This idea was further supported in a 
recent study by Pipes et al, in which these authors showed that although genetic deletion of 
myocardin is embryonic lethal, myocardin null mouse ES cells differentiated into SMC in 
culture, and when introduced into a chimeric mouse model gave rise to myocardin -/- SMC in 
the aorta(125). RT-PCR analyses revealed that MRTF-A was strongly expressed in 
myocardin -/- cells, and in wild-type cells, was expressed much earlier in development than 
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myocardin. Though myocardin null ES cells were able to differentiate into SMC and 
appeared to have normal contractile protein levels and function, many markers were 
dysregulated at the mRNA level, indicating myocardin as an important coordinator of gene 
transcription, a role of myocardin that was previously undemonstrated.  
IMPORTANT AREAS FOR FUTURE INVESTIGATION 
Expression Patterns of MRTFs in the Embryo and Adult Animal 
Clearly, more information is needed concerning the specific role of each myocardin 
factor in cardiovascular development. A more rigorous examination of tissue and cell-type 
distribution of the myocardin factors throughout development and in adult animals will be an 
important aim to pursue, so that their contributions to tissue-specific transcription can be 
more precisely determined. MRTF-A and MRTF-B expression have thus far been examined 
primarily by Northern and Western blotting. Because of this, it has been difficult to 
determine precisely which cell-types express these SRF co-factors. In situ analyses of 
MRTF-A and MRTF-B will be of great benefit to our understanding of these factors, but 
histological examination of protein expression will also be important. This is especially true 
in light of our recent finding that the myocardin factor levels are highly regulated by the 
ubiquitin-proteasome system, a post-translational pathway.  
The Role of Myocardin Factors in Cardiovascular Disease 
An important area of study that has received little attention thus far is the role of the 
myocardin factors in vascular disease. It is well established that down-regulation of SMC 
differentiation marker genes plays an important role in the pathogenesis of multiple 
cardiovascular diseases including atherosclerosis and restenosis, and that myocardin factors 
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are normally responsible for activation of these genes. Recent studies have suggested that 
estrogen and BMP may exert athero-protective effects via activation of the myocardin factors 
(73, 77). It will be interesting to directly compare intracellular localization patterns of the 
MRTFs in healthy and diseased vessels, and to determine whether the expression of the 
myocardin factors is up- or down-regulated at either the mRNA or protein level. It would be 
worthwhile to evaluate this in vascular injury models as well. 
Preferences of Myocardin Factors for SRF at Specific CARG elements 
Another persisting question is whether the myocardin family members discriminate 
between SRF bound to different CArG elements found in the same or different promoters, 
and if so, how? Unpublished studies from our laboratory have revealed that mutations to 
specific CArG elements in the SM α-actin promoter differentially affect transactivation by 
myocardin and MRTF-A, indicating that MRTF-A and myocardin may interact with separate 
CArG elements within the same promoter, again supporting the idea that these proteins serve 
non-redundant roles in SMC-specific transcription. Detailed chromatin immunoprecipitation 
(ChIP) analyses of all three myocardin family members will be useful for identifying which 
CArG elements are important for the function of these SRF co-factors, and may aid in further 
determining whether the myocardin factors bind CArG elements as homo-or hetero-dimers. 
Regulation of Myocardin Factors by the Ubiquitin-Proteasome System 
Our recent discoveries that the myocardin factors are degraded by the proteasome, 
that MRTF-A and MRTF-B are stabilized by the LIM-only protein FHL2, and that MuRF3 
may act as an E3 ubiqutin ligase for these factors constitute the establishment of a novel 
pathway for myocardin factor regulation. The description of this pathway has the potential 
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for far-reaching implications in the field. As mentioned above, little is known regarding the 
regulation of myocardin factor expression and activity in development and disease, and the 
importance of myocardin factor protein turnover to normal SMC and cardiomyocyte function 
has yet to be examined. It is interesting to postulate that UPS-mediated regulation of the 
myocardin factors may play a significant role in cardiac and smooth muscle lineage 
determination, as well as in normal vascular function. This is an area that warrants further 
investigation. It will also be interesting to determine whether the myocardin factors are 
differentially regulated by the UPS in cardiac and smooth muscle, and whether this has a 
bearing on the preference of myocardin factors for binding to SRF at promoters specific to 
each cell-type. Additionally, our demonstration of poly-ubiquitinated MRTF-A in SMC is the 
first indication that the myocardin factors are ubiquitinated at all. It will be important to 
determine whether these proteins are also subject to mono-ubiquitination or similar post-
translational modifications, and if so, what effect these modifications have on myocardin 
factor function. 
The Role of FHL2 and Related Proteins in Cardiovascular Development 
FHL2 is expressed specifically in the heart and vasculature (26) (67) (158) and we 
have shown that it increases myocardin and MRTF-A activity by protecting them from 
proteasomal degradation. A logical conclusion based on these data would be that FHL2 plays 
a critical role in cardiovascular development. However, genetic deletion of FHL2 in the 
mouse had no observed affect on cardiac or smooth muscle differentiation or function (25). 
Further interpretation of these results requires additional studies. In particular, it will be 
important to determine whether other FHL family members function redundantly with FHL2 
in the stabilization of myocardin factors. We observed similar expression patterns between 
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FHL1 and FHL2, and it is possible that FHL1 compensates for the loss of FHL2 in vivo. We 
have recently cloned FHL1 into mammalian expression vectors, and an important future goal 
is to evaluate the role of FHL1 in the stabilization of myocardin factors in culture. It will be 
important to evaluate this possibility in vivo by tandem deletion of these two genes.  
CLINICAL IMPLICATIONS 
It was recently estimated by the American Heart Association that over 80 million 
people in the United States suffer from one or more forms of cardiovascular disease 
including hypertension, coronary heart disease, stroke, and congestive heart failure. 
Cardiovascular disease is the number one cause of death in our country, and in 2004 alone, 
claimed nearly 870,000 lives. This number represents one third of all deaths that year, and 
nearly 20% of these occurred in individuals below the age of 65 (137). Phenotypic 
modulation of SMC plays a central role in the pathogenesis of nearly every major 
cardiovascular disease, and it follows that an increased understanding of the mechanisms 
governing SMC-specific gene expression will be useful in identifying potential drug targets. 
This is especially true in the treatment and prevention of atherosclerosis and post-
angioplasty restenosis. As discussed in the opening chapter of this dissertation, SMC that 
have undergone phenotypic switching contribute to these disease processes in many ways, 
including through increased proliferation and migration, and increased matrix and 
inflammatory cytokine production. The work presented in this dissertation has examined 
several proteins that may be useful drug targets for preventing phenotypic switching of SMC 
in at-risk patients. For example, the myocardin factors themselves are potent activators of 
contractile gene expression in SMC, and drugs that increase myocardin factor expression or 
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stability may reduce the role played by SMC in atherogenesis and restenosis. Drugs designed 
to increase expression of FHL2 may have a similar effect. Conversely, enzymes that down-
regulate myocardin factor activity, including the muscle-specific ring fingers, present 
potential targets for repression. Finally, our demonstration that the ubiquitin-proteasome 
system plays a role in the regulation of this transcriptional pathway may have the greatest 
potential for future use in a clinical setting. Proteasome inhibitors have recently proven 
efficacious in the treatment of certain cancer-types (66, 132), and based on the data presented 
here, it is interesting to speculate that they may also have a use in the treatment of 
cardiovascular disease. 
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APPENDIX 
INTRODUCTION 
A major technical limitation to studying the myocardin factors has been a lack of 
suitable antibodies against these proteins. Accordingly, the majority of studies published to 
date examining myocardin factor expression patterns have used Northern analyses and in situ 
hybridizations. Likewise, functional studies of the myocardin factors have relied heavily on 
ectopic expression of epitope-tagged myocardin factor proteins. Because we and others have 
demonstrated that the myocardin factors are post-translationally regulated, it will be 
important to also closely examine their protein expression patterns, as these may be different 
from those of mRNA. Additionally, our understanding of myocardin factor function will be 
strengthened by further examination of endogenous protein behavior. Each of these pursuits 
requires that antibodies be generated against each member of this important family of SRF 
co-factors.  
In the completion of this dissertation research, a highly specific monoclonal antibody 
was generated against MRTF-A that has been successfully used in Western analyses, 
immunoprecipitations, and indirect immunofluorescence studies. This antibody was 
generated in collaboration with the Immunology Core Facility at the University of North 
Carolina at Chapel Hill.  
MATERIALS AND METHODS 
 Generation of Antibody - Multiple regions of MRTF-A were identified that are 
evolutionally conserved but are not shared with myocardin or MRTF-B. Two of these regions 
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were selected as templates for antigen production based on many factors including primary 
sequences, Kyte-Doolittle hyrophilicity plots, Jameson-Wolf antigenic indices, and Emini 
surface probability plots. Purified peptides with sequences corresponding to either aa 603-
611 or aa 658-676 of murine MRTF-A were commercially obtained (Sigma-Genosys). 
Armenian hamsters were immunized with purified peptide, and hamster sera were screened 
for immunoreactivity with recombinant and endogenous MRTF-A protein by Western 
analysis. MRTF-A aintibody producing hamsters were sacrificed, and hybridomas were 
generated via fusion of B cells harvested from hamsters with P3x63-Ag8.653 murine 
myeloma cells. Hybridomas were grown in 96 well plates, and antibody-containing 
supernatants were evaluated by enzyme-linked immunosorbant assay for reactivity with 
MRTF-A peptide and by Western analysis for immunoreactivity with MRTF-A protein. 
Monoclonal antibody-producing cell lines were obtained by serial dilution of hybridomas, 
and MRTF-A antibody was purified using Protein G columns (Sigma). The monoclonal cell 
line chosen for final antibody purification was derived from mice immunized with MRTF-A 
peptide 603-611. 
 Plasmids and Proteins – In vitro translated myocardin, MRTF-A, and MRTF-B 
protein were generated using Promega’s TNT T7 Reticulocyte Lysate System.  pcDNA3.1-
myocardin, MRTF-A, and MRTF-B were used as templates in these reactions, and were 
gereous gifts Da-Zhi Wang (University of North Carolina at Chapel Hill). 
 Immunoprecipitations and Western Analyses – Rat aortic SMC were lysed in RIPA + 
0.5% triton X-100, and endogenous MRTF-A was precipitated from lysates using whole sera 
or purified MRTF-A antibody coupled to G protein beads (Sigma). Precipitants were washed 
3 times in RIPA and 1X in tris-buffered saline. All samples were boiled and subjected to 
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SDS-PAGE, transferred to nitrocellulose and imunoblotted using whole sera or purified 
MRTF-A antibody at 1:1000. Peroxidase-conjugated Affinipure Goat Anti-Armenian 
Hamster IgG was used as secondary antibody at 1:10,000 (Jackson Immunoresearch). 
 Indirect Immunofluorescence – Sphingosine-1-phospahte (1uM) treated SMC were 
fixed using 3.7% paraformaldehyde and permeabilized with 0.4% triton X-100 in phosphate-
buffered saline. Anti-MRTF-A antibody was added at 1:300, and MRTF-A localization was 
visualized by addition of FITC Anti-Hamster IgG at 1:1000 (Open Biosystems). Filamentous 
actin was visualized by addition of Texas Red phalloidin at 1:1000 (Invitrogen). 
RESULTS 
Purified hamster anti-MRTFA antibody detected in vitro transcribed and translated 
MRTF-A protein by Western analysis, and did not cross-react with highly homologous 
myocardin or MRTF-B (Fig 6.1B). Purified hamster anti-MRTF-A antibody also detected 
endogenous MRTF-A protein, as previously demonstrated (Fig 2.1). As can be seen in figure 
6.1B, this antibody also efficiently immunoprecipitated endogenous MRTF-A from SMC 
lystate. Subcellular localization of endogenous MRTF-A was examined in S1P-treated SMC 
by indirect immunofluorescence using purified hamster anti-MRTF-A antibody and FITC 
Anti-Hamster IgG (Fig 6.1C).  
DISCUSSION 
The antibody generated here, hamster anti-MRTF-A, has been very useful in the 
completion of this dissertation research, and will be a valuable tool for future studies of 
MRTF-A function. Immunization of hamsters with peptides corresponding to the same 
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regions of myocardin and MRTF-B may yield similarly efficacious antibodies for these 
proteins. This is a worthwhile pursuit, as its success would open the door to a wide array of 
studies that have this far been impossible. For example, ChIP analyses (as discussed in the 
previous chapter) performed in cells ectopically expressing epitope-tagged variants of the 
myocardin factors will certainly yield important data, but similar studies examining the 
behavior of endogenous myocardin factors would be much more useful. Likewise, 
examination of myocardin factor protein expression and localization patterns in development 
and disease requires that these antibodies be made available. In the meantime, we plan to 
begin detailed analyses of endogenous MRTF-A using the antibody described here. 
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